[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 36902
1. Maser RS, Choudhury B, Campbell PJ, Feng B, Wong KK, Protopopov A, O'Neil J, Gutierrez A, Ivanova E, Perna I, Lin E, Mani V, Jiang S, McNamara K, Zaghlul S, Edkins S, Stevens C, Brennan C, Martin ES, Wiedemeyer R, Kabbarah O, Nogueira C, Histen G, Aster J, Mansour M, Duke V, Foroni L, Fielding AK, Goldstone AH, Rowe JM, Wang YA, Look AT, Stratton MR, Chin L, Futreal PA, DePinho RA: Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature; 2007 Jun 21;447(7147):966-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we engineered lymphoma-prone mice with chromosomal instability to assess the usefulness of mouse models in cancer gene discovery and the extent of cross-species overlap in cancer-associated copy number aberrations.
  • Along with targeted re-sequencing, our comparative oncogenomic studies identified FBXW7 and PTEN to be commonly deleted both in murine lymphomas and in human T-cell acute lymphoblastic leukaemia/lymphoma (T-ALL).
  • These results indicate that murine and human tumours experience common biological processes driven by orthologous genetic events in their malignant evolution.

  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • SciCrunch. OMIM: Data: Gene Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Aug 10;406(6796):641-5 [10949306.001]
  • [Cites] Cell Cycle. 2005 Oct;4(10):1356-9 [16131838.001]
  • [Cites] Nat Genet. 2001 Jun;28(2):155-9 [11381263.001]
  • [Cites] Adv Cancer Res. 2001;83:209-54 [11665719.001]
  • [Cites] Nat Genet. 2001 Dec;29(4):459-64 [11694878.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Cell. 2002 Jun 28;109(7):811-21 [12110179.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):149-55 [12204535.001]
  • [Cites] Cell. 2003 Jan 24;112(2):243-56 [12553912.001]
  • [Cites] Nature. 2003 Feb 6;421(6923):643-8 [12540856.001]
  • [Cites] Cancer Res. 2003 Sep 1;63(17):5352-6 [14500367.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8188-96 [14678974.001]
  • [Cites] Nat Immunol. 2004 Mar;5(3):247-53 [14985712.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] Nature. 2004 Mar 4;428(6978):77-81 [14999283.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9067-72 [15199222.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4394-9 [15231645.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2954-63 [15254063.001]
  • [Cites] Cancer Lett. 2004 Sep 15;213(1):11-20 [15312679.001]
  • [Cites] Nat Genet. 2004 Oct;36(10):1084-9 [15361874.001]
  • [Cites] Science. 2004 Oct 8;306(5694):269-71 [15472075.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):557-72 [15475419.001]
  • [Cites] Genes Dev. 1991 Feb;5(2):160-74 [1995414.001]
  • [Cites] Cell. 1991 Aug 23;66(4):649-61 [1831692.001]
  • [Cites] Cell. 1995 Oct 20;83(2):289-99 [7585946.001]
  • [Cites] Nature. 1998 May 28;393(6683):382-6 [9620803.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] Cell. 1999 May 14;97(4):527-38 [10338216.001]
  • [Cites] Nature. 2004 Dec 9;432(7018):775-9 [15592418.001]
  • [Cites] Cell. 2004 Dec 17;119(6):847-60 [15607980.001]
  • [Cites] Cell. 2004 Dec 17;119(6):861-72 [15607981.001]
  • [Cites] Nat Genet. 2005 Jan;37(1):48-55 [15608639.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Nat Genet. 2005 Jun;37 Suppl:S11-7 [15920524.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):124-8 [15913747.001]
  • [Cites] Cancer Res. 2005 Dec 15;65(24):11361-6 [16357143.001]
  • [Cites] Blood. 2006 Jan 15;107(2):781-5 [16166587.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Apr;45(4):338-48 [16323170.001]
  • [Cites] Leukemia. 2006 Mar;20(3):537-9 [16424867.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5947-52 [16585505.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):313-25 [16616336.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1253-67 [16814713.001]
  • [Cites] Cell. 2006 Jun 30;125(7):1269-81 [16814714.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19848-53 [17167050.001]
  • [Cites] Cell Cycle. 2007 Apr 15;6(8):927-30 [17404512.001]
  • [Cites] Nat Cell Biol. 2005 Jul;7(7):706-11 [15965466.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9625-30 [15983384.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7591-5 [16140923.001]
  • [Cites] Oncogene. 2005 Oct 6;24(44):6597-604 [16007165.001]
  • [Cites] Blood. 2000 Sep 1;96(5):1940-6 [10961898.001]
  • (PMID = 17515920.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE7615
  • [Grant] United Kingdom / Wellcome Trust / / 077012; United Kingdom / Wellcome Trust / / 088340; United Kingdom / Medical Research Council / / G0500389; United Kingdom / Wellcome Trust / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC2714968; NLM/ UKMS27310
  •  go-up   go-down


2. Cózar Olmo JA, Martínez Colmenero C, Peláez Pleguezuelos I, Leiva Gea I, López García AB, de la Cruz Moreno J: [Carboxypeptidase-G2 administration after high-dose methotrexate. Treatment and drug interactions]. An Pediatr (Barc); 2009 Sep;71(3):230-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Administración de carboxipeptidasa tras altas dosis de metotrexato. Tratamiento e interacciones medicamentosas.
  • Methotrexate (MTX) is widely used as anticancer agent in various malignancies, including acute lymphoblastic leukaemia, lymphoma and osteosarcoma.
  • High doses of MTX may cause acute renal dysfunction.
  • More recently Carboxypeptidase-G2, a recombinant bacterial enzyme that rapidly hydrolyzes MTX to inactive metabolites, has become available for the treatment of acute nephrotoxicity.
  • We report a case of an adolescent who was diagnosed with T lymphoblastic lymphoma.
  • The literature was reviewed to study the influence of glutamine on delayed methotrexate elimination which may lead to acute toxicity.
  • [MeSH-major] Acute Kidney Injury / chemically induced. Acute Kidney Injury / drug therapy. Antimetabolites, Antineoplastic / adverse effects. Methotrexate / adverse effects. gamma-Glutamyl Hydrolase / therapeutic use

  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617010.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 3.4.19.9 / gamma-Glutamyl Hydrolase; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 17
  •  go-up   go-down


3. Ansari M, St-Onge G, Krajinovic M: [Pharmacogenomics of acute lymphoblastic leukemia]. Med Sci (Paris); 2007 Nov;23(11):961-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pharmacogenomics of acute lymphoblastic leukemia].
  • [Transliterated title] Pharmacogénétique de la leucémie lymphoblastique aiguë
  • Pharmacogenomics of acute lymphoblastic leukemia (ALL) evolved rapidly in the past few years.
  • Leukemia is the most common cancer affecting children, with ALL comprising 80 % of all leukemia cases.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18021708.001).
  • [ISSN] 0767-0974
  • [Journal-full-title] Médecine sciences : M/S
  • [ISO-abbreviation] Med Sci (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; E7WED276I5 / 6-Mercaptopurine; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Martins A, Cairoli H, Domínguez P, Martin S, Ortiz C, Potasznik J, Schenone N: [Nephromegaly: as unusual presentation of acute lymphoblastic leukemia in an infant]. Arch Argent Pediatr; 2008 Jun;106(3):263-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nephromegaly: as unusual presentation of acute lymphoblastic leukemia in an infant].
  • [Transliterated title] Nefromegalia: forma de presentación infrecuente de leucemia linfoblástica aguda en un lactante.
  • Nephromegaly in infancy may be due to several causes, being the most relevant: renal polycystic autosomic recessive disease, venous renal thrombosis, deposit diseases, kidney tumors, nephrotic congenital syndrome and neoplastic infiltration.
  • Although renal infiltration is relatively frequent in acute lymphoblastic leukemia, nephromegaly is an unusual form of presentation in this pathology.
  • Acute Lymphoblastic Leukemia is diagnosed, initiating the corresponding chemotherapic treatment.
  • [MeSH-major] Kidney / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18695841.001).
  • [ISSN] 1668-3501
  • [Journal-full-title] Archivos argentinos de pediatría
  • [ISO-abbreviation] Arch Argent Pediatr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


5. Dempsey RJ: Neurogenesis in Adults: Maybe You can Teach Old Dogs New Tricks after All! Neurosurgery; 2009 Apr 01;64(4):N12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neurogenesis in Adults: Maybe You can Teach Old Dogs New Tricks after All!

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28175563.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Cheok MH, Pottier N, Kager L, Evans WE: Pharmacogenetics in acute lymphoblastic leukemia. Semin Hematol; 2009 Jan;46(1):39-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacogenetics in acute lymphoblastic leukemia.
  • Progress in the treatment of acute lymphoblastic leukemia (ALL) in children has been remarkable, from a disease being lethal four decades ago to current cure rates exceeding 80%.
  • However, despite these high cure rates, the annual number of children whose leukemia relapses after their initial therapy remains greater than that of new cases of most types of childhood cancers.
  • These studies illustrate the promise of pharmacogenomics to further advance the treatment of human cancers, with childhood leukemia serving as a paradigm.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2000 Apr;14(4):567-72 [10764140.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):847-56 [10866211.001]
  • [Cites] Nature. 2000 Jun 15;405(6788):857-65 [10866212.001]
  • [Cites] Nat Genet. 2000 Oct;26(2):135-7 [11017062.001]
  • [Cites] Semin Hematol. 2000 Oct;37(4):381-95 [11071360.001]
  • [Cites] Clin Chem. 2001 Feb;47(2):164-72 [11159763.001]
  • [Cites] Nature. 2001 Feb 15;409(6822):928-33 [11237013.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2293-301 [11304783.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2948-58 [11387368.001]
  • [Cites] Genome Res. 2001 Jul;11(7):1262-8 [11435409.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7225-32 [11585759.001]
  • [Cites] Science. 2001 Nov 23;294(5547):1669-70 [11721042.001]
  • [Cites] Nat Rev Genet. 2001 Dec;2(12):930-42 [11733746.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2002;42:113-33 [11807167.001]
  • [Cites] Nat Rev Genet. 2002 May;3(5):391-7 [11988764.001]
  • [Cites] Cancer Res. 2002 Jun 1;62(11):3144-50 [12036927.001]
  • [Cites] Science. 2002 Jun 21;296(5576):2225-9 [12029063.001]
  • [Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):164-73 [12084458.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):133-43 [12086872.001]
  • [Cites] Curr Opin Pharmacol. 2002 Dec;2(6):723-9 [12482737.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):529-37 [12571261.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):538-49 [12571262.001]
  • [Cites] Haematologica. 2003 Mar;88(3):353-4 [12651279.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):518-21 [12652300.001]
  • [Cites] Nat Genet. 2003 May;34(1):85-90 [12704389.001]
  • [Cites] Nat Med. 2003 May;9(5):510-1 [12724758.001]
  • [Cites] Science. 2003 Jul 4;301(5629):102-5 [12843395.001]
  • [Cites] Pharmacogenetics. 2003 Sep;13(9):577-80 [12972956.001]
  • [Cites] Nat Biotechnol. 2003 Oct;21(10):1233-7 [12960966.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2951-9 [12730115.001]
  • [Cites] Nat Rev Genet. 2003 Dec;4(12):1001-8 [14631360.001]
  • [Cites] Cell Death Differ. 2004 Feb;11(2):165-74 [14576768.001]
  • [Cites] Pharmacogenomics J. 2004;4(1):66-72 [14647408.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):257-63 [14770183.001]
  • [Cites] Nat Genet. 2004 Mar;36(3):214-5 [14988717.001]
  • [Cites] Hum Mol Genet. 2004 Apr 1;13 Spec No 1:R57-64 [14764619.001]
  • [Cites] Mol Cell Biol. 2004 Apr;24(8):3347-58 [15060156.001]
  • [Cites] Nature. 2004 May 27;429(6990):464-8 [15164072.001]
  • [Cites] Cell Death Differ. 2004 Jul;11 Suppl 1:S45-55 [15243581.001]
  • [Cites] Pharmacogenetics. 2004 Aug;14(8):557-67 [15284538.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):533-42 [15295046.001]
  • [Cites] J Clin Oncol. 2004 Oct 1;22(19):3930-6 [15459215.001]
  • [Cites] J Biol Chem. 1980 Jun 25;255(12):5776-88 [6892914.001]
  • [Cites] Am J Hum Genet. 1980 Sep;32(5):651-62 [7191632.001]
  • [Cites] J Clin Invest. 1985 Sep;76(3):907-12 [2413074.001]
  • [Cites] N Engl J Med. 1986 Feb 20;314(8):471-7 [3456079.001]
  • [Cites] J Steroid Biochem. 1987;27(1-3):201-8 [3501039.001]
  • [Cites] Blood. 1990 Jul 1;76(1):44-9 [1694703.001]
  • [Cites] Lancet. 1990 Jul 28;336(8709):225-9 [1973780.001]
  • [Cites] J Pediatr. 1991 Dec;119(6):985-9 [1960624.001]
  • [Cites] Annu Rev Genet. 1991;25:281-314 [1687498.001]
  • [Cites] Blood. 1994 Jul 15;84(2):564-9 [7517720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):949-53 [7862671.001]
  • [Cites] Nat Biotechnol. 2005 Mar;23(3):377-83 [15765094.001]
  • [Cites] Leukemia. 2002 Aug;16(8):1437-42 [12145682.001]
  • [Cites] Steroids. 2005 May-Jun;70(5-7):407-17 [15862824.001]
  • [Cites] J Natl Cancer Inst. 2005 May 4;97(9):643-55 [15870435.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Nat Rev Cancer. 2001 Nov;1(2):99-108 [11905809.001]
  • [Cites] Pharmacogenetics. 2002 Apr;12(3):181-2 [11927832.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1033-4 [11937185.001]
  • [Cites] J Clin Invest. 1996 Jan 1;97(1):73-80 [8550853.001]
  • [Cites] Mol Cell Biol. 1997 Feb;17(2):895-905 [9001244.001]
  • [Cites] Ann Intern Med. 1997 Apr 15;126(8):608-14 [9103127.001]
  • [Cites] Blood. 1997 Oct 1;90(7):2723-9 [9326239.001]
  • [Cites] N Engl J Med. 1998 Feb 19;338(8):499-505 [9468466.001]
  • [Cites] Leukemia. 1998 Mar;12(3):346-52 [9529129.001]
  • [Cites] Blood. 1999 May 1;93(9):2817-23 [10216075.001]
  • [Cites] Cancer Res. 1999 Jun 1;59(11):2532-5 [10363967.001]
  • [Cites] Lancet. 1999 Jul 3;354(9172):34-9 [10406363.001]
  • [Cites] Blood. 1999 Aug 15;94(4):1209-17 [10438708.001]
  • [Cites] Science. 1999 Oct 15;286(5439):531-7 [10521349.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):110-7 [15630450.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):291-9 [15665306.001]
  • [Cites] Science. 2005 Feb 18;307(5712):1072-9 [15718463.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2482-7 [15781665.001]
  • [Cites] JAMA. 2005 Mar 23;293(12):1485-9 [15784872.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3053-8 [15833833.001]
  • [Cites] Cancer Cell. 2005 Apr;7(4):375-86 [15837626.001]
  • [Cites] Pharmacogenet Genomics. 2005 May;15(5):277-85 [15864128.001]
  • [Cites] Blood. 2005 Jul 15;106(2):717-20 [15797993.001]
  • [Cites] Nat Genet. 2005 Aug;37(8):878-82 [16041371.001]
  • [Cites] Nature. 2005 Oct 27;437(7063):1299-320 [16255080.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Annu Rev Med. 2006;57:119-37 [16409140.001]
  • [Cites] Leukemia. 2006 Feb;20(2):239-46 [16341039.001]
  • [Cites] Leukemia. 2006 Jan;20(1):9-17 [16281070.001]
  • [Cites] Blood. 2006 Jul 15;108(2):711-7 [16822902.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1050-7 [16627760.001]
  • [Cites] Haematologica. 2006 Aug;91(8):1113-6 [16870553.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1929-35 [17008526.001]
  • [Cites] Cancer Cell. 2006 Oct;10(4):331-42 [17010674.001]
  • [Cites] Nat Biotechnol. 2006 Sep;24(9):1151-61 [16964229.001]
  • [Cites] Clin Pharmacol Ther. 2006 Nov;80(5):468-76 [17112803.001]
  • [Cites] Science. 2007 Jan 26;315(5811):525-8 [17185560.001]
  • [Cites] Nature. 2007 Apr 12;446(7137):758-64 [17344859.001]
  • [Cites] Blood. 2007 May 1;109(9):3929-35 [17218380.001]
  • [Cites] Science. 2007 Apr 27;316(5824):550-1 [17463274.001]
  • [Cites] Blood. 2007 May 15;109(10):4151-7 [17264302.001]
  • [Cites] Nature. 2007 May 10;447(7141):161-5 [17495918.001]
  • [Cites] Nat Genet. 2007 Jul;39(7 Suppl):S7-15 [17597783.001]
  • [Cites] Blood. 2007 Aug 15;110(4):1271-7 [17456722.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13513-8 [17686970.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1429-38 [17495134.001]
  • [Cites] Hum Mol Genet. 2007 Oct 1;16(19):2261-71 [17616514.001]
  • [Cites] Leukemia. 2007 Oct;21(10):2128-36 [17673902.001]
  • [Cites] Haematologica. 2007 Nov;92(11):1561-4 [18024406.001]
  • [Cites] Methods. 2008 Jan;44(1):22-30 [18158129.001]
  • [Cites] Blood. 2008 Mar 15;111(6):2984-90 [18182569.001]
  • [Cites] Blood. 2008 Apr 1;111(7):3692-700 [18096764.001]
  • [Cites] Blood. 2008 May 1;111(9):4496-9 [18285546.001]
  • [Cites] PLoS Med. 2008 Apr 15;5(4):e83 [18416598.001]
  • [Cites] PLoS One. 2008;3(5):e2144 [18478092.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jun;18(6):507-14 [18496130.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 17;100(24):1792-803 [19066270.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):1049-57 [17380207.001]
  • [Cites] J Natl Cancer Inst. 1999 Dec 1;91(23):2001-8 [10580024.001]
  • [Cites] Int J Hematol. 1999 Dec;70(4):268-77 [10643153.001]
  • [Cites] Mol Cell Biol. 2000 Mar;20(6):2004-13 [10688647.001]
  • (PMID = 19100367.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA036401-25; United States / NCI NIH HHS / CA / R37 CA36401; United States / NIGMS NIH HHS / GM / U01 GM061393; United States / NCI NIH HHS / CA / R01 CA078224; United States / NCI NIH HHS / CA / R37 CA036401; United States / NCI NIH HHS / CA / CA21765; United States / NIGMS NIH HHS / GM / U01 GM61393; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA036401-25; United States / NCI NIH HHS / CA / R01 CA78224
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 120
  • [Other-IDs] NLM/ NIHMS89418; NLM/ PMC2665795
  •  go-up   go-down


7. Mateo J, Abarzuza R, Núñez E, Cristóbal JA: [Bilateral optic nerve infiltration in acute lymphoblastic leukemia in remission]. Arch Soc Esp Oftalmol; 2007 Mar;82(3):167-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral optic nerve infiltration in acute lymphoblastic leukemia in remission].
  • [Transliterated title] Infiltración bilateral del nervio óptico en un caso de leucemia aguda linfoblástica de células T en remisión.
  • CASE REPORT: An 18-year-old male affected by acute lymphoblastic leukemia (ALL) after having reached complete remission after chemotherapy developed bilateral optic nerve infiltration.
  • [MeSH-major] Leukemic Infiltration. Optic Nerve / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Fundus Oculi. Humans. Male. Papilledema / diagnosis. Prognosis. Recurrence. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357894.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


8. Benítez Velazco A, González García FM, Albalá González MD, Pacheco Capote C, Latre Romero JM: [Bone scintigraphy with 99mTc-MDP in a patient with acute lymphoblastic leukemia initially diagnosed of Still's disease]. Rev Esp Med Nucl; 2005 Sep-Oct;24(5):319-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bone scintigraphy with 99mTc-MDP in a patient with acute lymphoblastic leukemia initially diagnosed of Still's disease].
  • [Transliterated title] Gammagrafía ósea con 99mTc-MDP en un paciente con leucemia aguda linfoblástica diagnosticado inicialmente de enfermedad de Still.
  • We present a 43-year-old male, who was admitted with the diagnosis of Adult-onset Still's disease, after several months of arthralgias, febricula and loss of weight.
  • Scintigraphic findings oriented to the performance of a bone marrow biopsy with diagnosis of acute lymphoblastic leukemia.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / radionuclide imaging. Radiopharmaceuticals. Still's Disease, Adult-Onset / diagnosis. Technetium Tc 99m Medronate

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194464.001).
  • [ISSN] 0212-6982
  • [Journal-full-title] Revista española de medicina nuclear
  • [ISO-abbreviation] Rev Esp Med Nucl
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; X89XV46R07 / Technetium Tc 99m Medronate
  •  go-up   go-down


9. Duffin C: Court overrules 'unduly lenient' NMC misconduct judgement. Nurs Stand; 2005 Nov 02;20(8):12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Court overrules 'unduly lenient' NMC misconduct judgement.
  • : A nurse who escaped punishment when she was found guilty of professional misconduct by the Nursing and Midwifery Council (NMC) is to face sanctions after all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27978254.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Bates J: Fighting fit. Nurs Stand; 2009 Oct 21;24(7):25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fighting fit.
  • : 'All nurses have bad backs,' the GP said, dismissively.
  • I do not think he shouted 'Next!
  • ' but he might as well have done.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28033816.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. What you need to know about cannabis - understanding the facts David Emmett What you need to know about cannabis - understanding the facts and Graeme Nice Jessica Kingsley Publishers 128pp £12.99 978 1 84310 697 5 1843106973 [Formula: see text]. Nurs Stand; 2009 Jun 03;23(39):30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What you need to know about cannabis - understanding the facts David Emmett What you need to know about cannabis - understanding the facts and Graeme Nice Jessica Kingsley Publishers 128pp £12.99 978 1 84310 697 5 1843106973 [Formula: see text].
  • : This is an extremely readable and up to date book about all aspects of cannabis and cannabis use, amply illustrated with diagrams and photographs.
  • It is informative and balanced, as well as being well written, interesting and accessible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27996850.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Bates J: Nursing fever. Nurs Stand; 2007 Mar 07;21(26):28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nursing fever.
  • : Job at risk? Facing redundancy?
  • Aren't we all?
  • Every now and then I daydream of early retirement: leisurely breakfasts with the papers, splashing out on luxury trips with my NHS pension.
  • Yes, the worry is making me hallucinate.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27967434.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Uncovering Skills for Practice Carol Chapelow et al Uncovering Skills for Practice Nelson Thornes 184pp , £11.70 0 7487 9261 9 0748792619 [Formula: see text]. Nurs Stand; 2006 Jan 04;20(17):36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Uncovering Skills for Practice Carol Chapelow et al Uncovering Skills for Practice Nelson Thornes 184pp , £11.70 0 7487 9261 9 0748792619 [Formula: see text].
  • : Part of the Foundations in Nursing and Health Care Series, this easy to read text offers something for all.
  • Students will find the clear explanations concise and informative, and trained staff will find the mini exercises useful in assisting learners.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990925.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Ward to board leadership. Nurs Stand; 2009 Oct 14;24(6):24-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ward to board leadership.
  • : Nursing directors are supposed to ensure that clinical quality features frequently on the agendas of NHS board meetings and is monitored at board level.
  • On the face of it, nurse directors are ideally placed to promote clinical quality.
  • After all, nurses and midwives are seen as key to providing quality care.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28080695.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Pay cut after 'best year'? Nurs Stand; 2006 Nov 01;21(8):1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pay cut after 'best year'?
  • : When governments boast about how well the health service is performing under their stewardship - usually the number of patients treated and how quickly - they are really describing the achievements of staff in hospitals and the community.
  • After all, no minister has ever actually walked into a treatment centre or a patient's home and delivered care themselves.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28010483.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Terms of endearment. Nurs Stand; 2008 Dec 03;23(13):13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Terms of endearment.
  • : Some nurses address their older patients as 'love' or 'dearie' simply as a term of endearment.
  • Others say it because they have forgotten the names of their patients.
  • But what is clear from new Nursing and Midwifery Council (NMC) guidance is that no nurse should be using those terms at all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28010406.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Fowell M: 'damaged' nurses require support and not exclusion. Nurs Stand; 2010 Oct 27;25(8):32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 'damaged' nurses require support and not exclusion.
  • : Further to your news story, 'Regulator reveals plans to prevent enrolment of "damaged" students' (October 20), I am concerned by any plans to cut certain people out of society like a cancer.
  • Health care is all about helping people become independent and productive achievers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28034104.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


18. Bhargava P, Esteves B, Nosov DA, Lipatov ON, Lyulko AA, Anischenko AA, Chacko RT, Lee P, Al-Adhami M, Ryan J: Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC). J Clin Oncol; 2009 May 20;27(15_suppl):5032
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Updated activity and safety results of a phase II randomized discontinuation trial (RDT) of AV-951, a potent and selective VEGFR1, 2, and 3 kinase inhibitor, in patients with renal cell carcinoma (RCC).
  • 53% pts were treatement naïve, 72% had undergone nephrectomy and 83% had RCC with clear cell component.
  • With a median duration of treatment of 5 mo (range 0-12 mo), the investigator assessed ORR (CR+PR) is 27.2% (30% in clear cell RCC), SD 60.5% and Disease Control Rate (CR/PR + SD) 88%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962939.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Hanrahan EO, Kim F, Lin HY, Tran HT, Ryan AJ, Krebs AD, Lee JJ, Johnson BE, Heymach JV, Kim ES: Plasma cytokine concentrations and quality of life in patients with non-small cell lung cancer in a phase II trial of first-line treatment with carboplatin-paclitaxel and/or vandetanib. J Clin Oncol; 2009 May 20;27(15_suppl):9596
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasma cytokine concentrations and quality of life in patients with non-small cell lung cancer in a phase II trial of first-line treatment with carboplatin-paclitaxel and/or vandetanib.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963731.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Hauser KA, Karafa M, Seyidova-Khoshknabi D, Davis MP, Walsh D: Prevalence and risk factors of vitamin D insufficiency in cancer. J Clin Oncol; 2009 May 20;27(15_suppl):9581
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Insufficiency was associated with male gender, race (African American), month of test (Feb-Apr, Oct), cancer type (hepatobiliary, genitourinary, pancreas, upper gastrointestinal), metastatic disease, low albumin, high bilirubin and AST, and lack of antineoplastic or vitamin D medication (all p<0.01).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963701.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Liu H, Sloan JA, Sargent DJ, Satele DV, Schaefer PL, Halyard MY, Grothey A, Garces YI, Brown PD, Buckner JC: Assessing simple measures of patient-reported (PR) fatigue for oncology clinical trials: A pooled analysis of 3,915 patients. J Clin Oncol; 2009 May 20;27(15_suppl):9563
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing simple measures of patient-reported (PR) fatigue for oncology clinical trials: A pooled analysis of 3,915 patients.
  • : 9563 Background: Fatigue is a prevalent and debilitating symptom reported by cancer patients (pts) which compromises a pt's quality of life (QOL).
  • This study examined the relationship between PR fatigue and QOL as well as cancer-related symptoms (CRS) in 43 North Central Cancer Treatment Group and Mayo Clinic Cancer Center clinical trials.
  • METHODS: 3,915 pts from 43 oncology clinical trials provided baseline fatigue data on a single-item 0-100 point scale.
  • Pts' QOL assessment included a single-item overall QOL and associated QOL domains measured by numerical analogues, the Profile of Mood States (POMS), and PR symptom assessment measures.
  • Associations between fatigue and QOL domains were assessed by Spearman correlation coefficients.
  • Wilcoxon rank sum test compared QOL scores between pts with clinically deficient fatigue(CDF, score ≤50) vs. no clinically deficient fatigue (nCDF, score>50).
  • Changes from baseline in fatigue and QOL were compared by Wilcoxon rank sum test with a 20-point change defined as clinically meaningful.
  • RESULTS: 38% of pts reported CDF at baseline and 45% of pts reported CDF at last assessment.
  • Fatigue was only moderately correlated at best with overall QOL, pain, POMS, social and physical function (Spearman rho's of .27,.40, .56, .38 and .38 respectively).
  • Pts with CDF averaged over 10 points lower overall QOL, pain, POMS, social, and physical function (see table below, all p<.0001) as well as worsening CRS including sleepiness, nausea, headache, abnormal sweating, trouble sleeping, dry mouth, and sexual dysfunction (all p<.001).
  • Pts with 20+ points worsening in fatigue declined in overall QOL, physical function, pain and POMS (all p<.0001).
  • CONCLUSIONS: Patients with CDF suffer greater deficits in QOL and CRS.
  • Patients report fatigue as distinctly different from overall QOL, pain, physical, social, mood status and CRS.
  • Fatigue appears with a broad spectrum of CRS clusters.
  • Routine measurement and management of fatigue could impact QOL and treatment-related symptoms.
  • [Table: see text] No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963633.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Crino L, Mezger J, Griesinger F, Zhou C, Reck MM: MO19390 (SAiL): Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):8043
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MO19390 (SAiL): Safety and efficacy of first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC).
  • METHODS: Primary endpoint was safety; secondary endpoints included time to disease progression (TTP) and overall survival (OS).
  • Pts with untreated locally advanced, metastatic or recurrent non-squamous NSCLC (ECOG PS 0-2) received Bv (7.5 or 15mg/kg) with standard chemotherapy for up to six cycles, then non-progressors proceeded to receive Bv until disease progression.
  • Pts (%) were: male 60.1; stage IIIB/IV 19.5/80.5 (no data 3 pts); adenocarcinoma/large cell/other 85.8/7.1/7.1; ECOG PS 0/1/2 38.1/56.1/5.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962850.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Smith J, Benjamin M, Yim JH, James RL, Ramanathan RK, Anthony SP, Borad M, Bay RC, Piper BF, Tibes R: Prospective evaluation of patient perceptions and willingness to undergo pharmacodynamic and pharmacokinetic tests in early phase oncology trials. J Clin Oncol; 2009 May 20;27(15_suppl):6587
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 6587 Background: Increasing numbers of clinical trials include optional or mandatory pharmaco-dynamic and -kinetic assays.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963864.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Vicus D, Beiner M, Klachook S, Le L, Ginsburg O, Laframboise S, Mackay H: Dysgerminoma of the ovary 35 years on: A single institutional experience. J Clin Oncol; 2009 May 20;27(15_suppl):e16523
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 40 pts (62.5%) presented with FIGO stage IA disease; 3 (4.7%) stage IB; 6 (9.4%) stage IC; 2 (3.1%) stage II; and 13 (20.3%) at stage III, 1 unknown.
  • 17 pts received chemotherapy, 15 adjuvant and 2 for residual disease (all post 1988); 8 for stage I, 1 for stage II, and 8 for stage III.
  • 6 (9.2%) pts recurred all within 19 months of initial diagnosis.
  • 5 of the 6 pts that recurred had stage IA disease treated with a unilateral oophorectomy, 1 received adjuvant EP.
  • 1 pt with stage IIIC disease recurred following bilateral oophorectomy + hysterectomy and radiotherapy.
  • Treatment of recurrent disease was by salvage surgery and chemotherapy (3 pts), radiotherapy (2 pts), and EP (1 pt).
  • Recurrences occured within 2 years of diagnosis and are treatable.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960796.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Policzer J, Kinzbrunner B, Tanis D: Seasonal mortality in terminally ill cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):6575
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this paper, we compare seasonal variation in death rates for terminally ill cancer patients to terminally ill patients who are "frail," i.e., those with neurodegenerative disease, general debility, or chronic heart failure.
  • The 72,066 records were analyzed using a three-way analysis of variance (season, place of care, diagnosis) with Bonferroni correction for post-hoc comparisons.
  • These include a smaller "symptom burden" than frail patients, who frequently have comorbid disease(s) and who are often unable to make their needs known; less compromised immune systems; more aggressive medical treatment; better nutrition; a strong support system (particularly from family and caregivers); and increased sensitivity to factors that may prolong survival, e.g., timely immunizations and even the avoidance of crowds in winter months.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963828.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Olmos D, Allred A, Sharma R, Brunetto A, Smith D, Murray S, Barker D, Taegtmeyer A, de Bono J, Blagden S: Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):3536
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other Sch 2 AEs with a maximum grade ≥3 were PE, renal failure, thrombocytopenia, and catheter-related infection (all n = 1).
  • Stable disease >5m has been observed in 2 esophageal cancer pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961338.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Latreille J, Samson A, Tran U, Mimeault C, Boily C, Laflamme B, Loutfi A: Implementation of an integrated cancer care network. J Clin Oncol; 2009 May 20;27(15_suppl):e17564
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 2004, a team evaluation process was initiated by the Direction de la lutte contre le cancer (ministry of health) to help implement this program.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963842.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Holmström R: Beyond black and white. Nurs Stand; 2010 Oct 13;25(6):62-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond black and white.
  • : 'Assumptions based on a patient's appearance may well have an effect on clinical judgements - but that is not all,' says RCN diversity and equalities co-ordinator Wendy Irwin.
  • 'If patients do not feel understood at a time when they are at their most vulnerable, that is an important issue of dignity and one that nurses specifically should keep in mind. '

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28029951.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Black S: The power of compassion. Nurs Stand; 2008 Oct 22;23(7):70-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The power of compassion.
  • : If you are thinking of becoming a nurse or have just embarked on a nursing course, one of the main characteristics you hope to bring to the role is likely to be compassion.
  • After all, compassion is what nurses do, isn't it?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28006377.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


30. Nurses have rights too. Nurs Stand; 2006 Nov 22;21(11):1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nurses have rights too.
  • : Nursing is a profession that deals with the vulnerable.
  • Nurses have to be trusted by everyone they deal with, including their colleagues, peers and, above all, the public.
  • That overwhelmingly they are trusted, and that they rarely fail in their responsibilities and duties, is a testament to their professionalism.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001881.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


31. Allen D: Standard life-In these uncertain days, Daniel Allen shares his 'future-proofing' tips to help nurses toughen up. Nurs Stand; 2006 Nov 08;21(9):25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standard life-In these uncertain days, Daniel Allen shares his 'future-proofing' tips to help nurses toughen up.
  • : Are you future-proofed? Me neither.
  • All I can deal with is the here and now.
  • But everywhere I look people are talking about future-proofing their practice.
  • GPs are at it, police officers, lawyers, teachers - even, I suspect, clairvoyants.
  • What is it all about and should nurses be doing it, too?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27986006.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


32. Have a look at the other side of the work/life balance. Nurs Stand; 2007 Aug 01;21(47):32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Have a look at the other side of the work/life balance.
  • : Has nursing become the most selfish profession of all?
  • We constantly moan about night shifts, how staff shortages and deficits are detrimental to quality patient care and nursing intervention, and how this limits our ability to provide the highest standards of nursing.
  • On the other hand, I cannot help but notice how we seem to forget to look after each other when it comes to shift allocation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001636.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Reservists seek more support from managers and staff. Nurs Stand; 2008 Oct 22;23(7):12-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reservists seek more support from managers and staff.
  • : Being a reservist in the Royal Navy is not all about spending weekends on ships or training for combat.
  • By joining the 1,600 members of the NHS in the UK's reserve forces, nurses can gain key clinical and leadership skills, as well as taking part in life-saving humanitarian missions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28006359.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


34. The biological basis of nursing - cancer William T Blows The biological basis of nursing - cancer Routledge 360pp £;20.99 0 415 32746 6 0415327466 [Formula: see text]. Nurs Stand; 2005 Dec 07;20(13):36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The biological basis of nursing - cancer William T Blows The biological basis of nursing - cancer Routledge 360pp £;20.99 0 415 32746 6 0415327466 [Formula: see text].
  • : William Blows begins the introduction to this book by stating: 'Life is all about biology.
  • ' He believes most of us are guilty of seeing biology as just a subject, rather than an actual living and happening event around us and driving us.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28001787.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


35. Newnham D: Outsidein - the euro health insurance card expires. David Newnham thinks he knows why. Nurs Stand; 2009 Apr 08;23(31):26-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outsidein - the euro health insurance card expires. David Newnham thinks he knows why.
  • : Shock, horror, read all about it - millions of European Health Insurance Cards (EHICs) are about to expire.
  • Feckless Brits face Euro- holiday hell.
  • Department of Health (DH) calls in TV doctor.
  • Honestly, anyone would think avian flu had suddenly landed at Gatwick.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27996519.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


36. Bates J: Quality is key. Nurs Stand; 2009 Apr 29;23(34):27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quality is key.
  • : Do you have targets in your life?
  • I suppose we all do.
  • Mine are generally domestic.
  • For example, by next Christmas I will have caught up with the ironing.
  • It is overambitious, I know, and unlikely to happen, but if I do not at least have a target then there is no hope at all.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27991067.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


37. Tercyak K, Peshkin B, DeMarco T, Schneider K, Valdimarsdottir H, Garber J, Patenaude A: Parental decisions and outcomes regarding disclosing maternal BRCA1 and 2 test results to children. J Clin Oncol; 2009 May 20;27(15_suppl):9582
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parental decisions and outcomes regarding disclosing maternal BRCA1 and 2 test results to children.
  • : 9582 Background: BRCA1/2 testing is key to hereditary cancer risk management.
  • Though testing is discouraged in children, prior work suggests they are informed of their tested mothers' mutation status; decisions and outcomes of parental disclosure to children remain largely unknown.
  • METHODS: We examined predictors of parental disclosure decisions to children ages 8-21 and related outcomes in a large clinical sample (221 tested mothers, 124 untested co-parents).
  • Parents were interviewed prior to mothers' receipt of BRCA1/2 results and 1 and 6 months later.
  • Descriptive analyses were conducted, and bivariate analyses identified candidate predictor variables (demographic, medical, psychosocial) for inclusion in multivariate logistic regression models.
  • RESULTS: 63% of mothers disclosed their results to their children within 1 month of receipt (44% of co-parents also disclosed to children); this increased to 68% by 6 months (55% among co-parents).
  • Within parenting dyads, mothers were significantly more likely than co-parents to disclose to children in the short-term (X<sup>2</sup>=18.6, p<.0001).
  • Predictors of maternal disclosure to children included not being a BRCA1/2 mutation carrier, older child age, stronger intentions to disclose, more favorable attitudes toward pediatric BRCA1/2 testing, a more open parent-child communication history, and a decisional balance favoring disclosure (all p's<.05).
  • When examined simultaneously, mothers who were not mutation carriers (OR=4.02, 95% CI=1.35, 11.94), mothers of older children (OR=1.30, 95% CI=1.13, 1.49), and those with stronger intentions to disclose (OR=1.39, 95% CI=1.10, 1.76) were more likely to communicate.
  • Other outcomes of maternal disclosure included greater satisfaction with the decision to disclose and more open parent-child communication following disclosure (all p's<.05).
  • CONCLUSIONS: This is the largest and most well-characterized study on this topic to date.
  • Short-term rates of parental disclosure to children were high, increasing over time.
  • Parental disclosure decisions are determined by a complex array of both child and parent factors, with some benefits identified with disclosure.
  • Findings indicate a need for additional work, including decision support interventions for communication with children.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963706.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. What price this pay rise? Nurs Stand; 2007 Mar 07;21(26):1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] What price this pay rise?
  • : There was outrage when a trust suggested that staff should work a day for free to help its finances.
  • And rightly so.
  • But now it seems the same principle is being applied nationally.
  • That really is the only conclusion to be drawn from the decision to stage your 2007 pay award.
  • After all, an independent review body looked at all the evidence, including ministers' arguments about affordability, and decided that a fair award this year would be 2.5 per cent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27967387.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Szczepanska S, Scullion J, Holyoake DD, Brown J: Stars fall to earth. Nurs Stand; 2005 Jan 12;19(18):26-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stars fall to earth.
  • : Everyday concerns count more As an NHS employee, I must admit I could not care less about star ratings.
  • I certainly do not feel I should leave my trust to work in another one with a higher star rating.
  • I do not feel stars reflect performance accurately at all.
  • If a hospital is failing in certain areas why not just point it out and let it make changes?
  • Maybe the new grading system will be fairer, but I will wait and see.
  • As a patient due to have surgery shortly, I have no idea what star rating the hospital has.
  • And as long as I survive the surgery, am nursed in a clean ward and do not catch an infection, I do not care how the trust is rated.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27985052.001).
  • [ISSN] 2047-9018
  • [Journal-full-title] Nursing standard (Royal College of Nursing (Great Britain) : 1987)
  • [ISO-abbreviation] Nurs Stand
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


40. Xu Y, Fan J, Yang X, Zhou J, Qiu S: High expression levels of putative hepatic stem/progenitor cells biomarkers related to tumor angiogenesis and poor prognosis of hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e22121
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression levels of putative hepatic stem/progenitor cells biomarkers related to tumor angiogenesis and poor prognosis of hepatocellular carcinoma.
  • : e22121 Background: To investigate the prognostic values of putative hepatic stem/progenitor cells (HSCs/HPCs) biomarkers in hepatocellular carcinoma (HCC) patients.
  • METHODS: Fourteen biomarkers related with HSCs/HPCs or tumor angiogenesis were assessed by qRT-PCR and then validated by tissue microarrays (TMAs) in three independent cohorts of HCC patients underwent curative resection (n=67, 314 and 73).
  • RESULTS: Most of the biomarkers were found over-expressed in recurrent HCC patients by qRT-PCR.
  • HSCs/HPCs biomarkers cytokeratin 19, ABCG2, CD133, Nestin, CD44 and angiogenesis agents CD34, VEGF and PD-ECGF, were confirmed as significant predictors for overall survival (OS) and/or relapse-free survival (RFS) in TMAs analysis.
  • Compared with the low HSCs/HPCs profile group, patients with high HSCs/HPCs profile had significantly lower OS and RFS (p<0.0001), expressed higher VEGF levels (p = 0.012) and microvessel density (MVD, determined by CD34 immunostaining, p = 0.030).
  • Based on Cox regression, a simplified model including CD133, CD44, Nestin, and MVD was constructed and confirmed as an independent predictor for OS (p<0.0001) and RFS (p<0.0001), regardless of alpha-fetoprotein level, tumor stage and recurrence time (p<0.0001 for all).
  • CONCLUSIONS: High expression levels of HSCs/HPCs biomarkers are related to tumor angiogenesis and poor prognosis of HCC.
  • The simplified model based on HSCs/HPCs and tumor angiogenesis profile can be used to classify HCC patients with high risk of tumor recurrence after operation.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963559.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Tucker K Esq: End-of-life care: Empowering cancer patients with information and choices. J Clin Oncol; 2009 May 20;27(15_suppl):e20739
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] End-of-life care: Empowering cancer patients with information and choices.
  • : e20739 Background: Terminally ill patients want information and choices, including aid in dying, as they confront death due to cancer and other terminal illnesses.
  • Physicians treating such patients want to feel safe in having candid conversations with patients about their wishes and to provide aid in dying when appropriate.
  • METHODS: Review the law governing end of life decision making, including aid in dying.
  • Review the data from Oregon, which has more than 10 years experience with a regulated practice.
  • Review what has been learned in OR, and how that is transferring to other states making aid in dying an end of life option.
  • RESULTS: Oregon's experience shows that when aid in dying is a legal option for mentally competent terminally ill patients overall end of life care improves.
  • Conversations between physicians and patients are more open and candid; Referrals to hospice increase and occur earlier; clinician enrollment in CE for pain and symptom management increase; rx of strong pain medication increase; more patients die at home; patients are comforted to have aid in dying as an option; there is no negative impact on the practice of medicine.
  • CONCLUSIONS: Terminally ill patients should be able to recieve comprehensive counseling about all end of life options.
  • There is a growing trend of support for expanding end of life options to include aid in dying for mentally competent terminally ill patients who find themselves trapped in an unbearable dying process.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962041.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Al-Khyatt W, Syed BM, Morgan DA, Cheung KL: Primary endocrine therapy for early operable primary breast cancer in elderly women: A large series from a single institution. J Clin Oncol; 2009 May 20;27(15_suppl):630
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients had disease assessable for response according to UICC criteria, and had treatment for ≥6 months unless the disease progressed prior.
  • When the disease progressed, some patients received further lines of therapy and the overall results are summarised (Table).
  • CR: complete response; PR: partial response; SD: stable disease; CB: clinical benefit = CR + PR + SD; PD: progressive disease; DoCB: duration of CB; TTP: time to progression (all in months).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961443.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Sleight DA, Mavis BE: Study Skills and Academic Performance among Second-Year Medical Students in Problem-Based Learning. Med Educ Online; 2006 Dec;11(1):4599
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study Skills and Academic Performance among Second-Year Medical Students in Problem-Based Learning.
  • PURPOSE: This research study highlights the relationship between study aid use and exam performance of second year medical students.
  • It also discusses how students used study aids in preparing for PBL exams and whether students who used others' study aids performed as well as students who created their own.
  • METHODS: A questionnaire was distributed to second-year medical students after completion of their exam.
  • The data from the questionnaire were linked to students' examination scores and other academic indicators.
  • RESULTS: The study habits were more similar than different when compared by exam performance.
  • A majority of students used study aids as a memory aid or for review, but students who performed in the top third of the class were less likely to use them at all.
  • Pre-existing differences related to academic achievement and study strategies were found when students at the top, middle and bottom of exam performance were compared.
  • CONCLUSIONS: A better understanding of the differences in study habits and study aid use in relation to examination performance can help in providing future students with appropriate academic support and advising.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28253787.001).
  • [ISSN] 1087-2981
  • [Journal-full-title] Medical education online
  • [ISO-abbreviation] Med Educ Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Wilson CR, Sherritt L, Knight JR: Teaching Residents about Child Neglect and Parental Alcoholism: A Controlled Pilot Study. Med Educ Online; 2005 Dec;10(1):4381
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Teaching Residents about Child Neglect and Parental Alcoholism: A Controlled Pilot Study.
  • OBJECTIVE: To assess in pediatric residents the effects of a case-based educational exercise about child neglect and parental alcoholism on their knowledge and attitudes.
  • DESIGN: Quasi-experimental controlled trial of a standardized educational intervention and qualitative analysis of residents' reactions.
  • SETTING: Resident continuity clinic conferences at a large pediatric teaching hospital.
  • PARTICIPANTS: Convenience sample of pediatric residents (n=37).
  • The residents in the control group received no intervention at all, while residents in the intervention group received the educational intervention.
  • INTERVENTION: A structured, 40-minute case discussion ("The Silent Cry") facilitated by trained faculty.
  • MAIN OUTCOME MEASURES: Learner ratings of materials and methods.
  • Pre/post change in scores on a knowledge quiz and attitude scale.
  • Codes and themes generated from qualitative analysis of focus group transcripts.
  • RESULTS: Intervention group residents rated the experience highly.
  • The two groups did not differ significantly in mean pre-post change on the knowledge quiz or attitude scale.
  • Focus group discussions revealed feelings of frustration and powerlessness when dealing with child neglect and parental alcoholism.
  • CONCLUSIONS: While this standardized educational intervention was well received by residents, more time is needed for discussion and multiple teaching sessions may be required.
  • Discussion of emotional responses should be included as a standard part of the educational experience.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28253138.001).
  • [ISSN] 1087-2981
  • [Journal-full-title] Medical education online
  • [ISO-abbreviation] Med Educ Online
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Child Neglect / Medical Education / Pediatrics / Substance Abuse
  •  go-up   go-down


45. Drabkin HA, Sharma G, Costa LJ, Korch C, Gemmill RM: Synergistic growth inhibition of RCC and NSCLC cell lines by sorafenib plus vorinostat and induction of angiogenic genes by ER stress. J Clin Oncol; 2009 May 20;27(15_suppl):e16114
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic growth inhibition of RCC and NSCLC cell lines by sorafenib plus vorinostat and induction of angiogenic genes by ER stress.
  • : e16114 Sorafenib, vorinostat and the combination were examined in 34 RCC and NSCLC cell lines.
  • In growth assays, sorafenib at 8 μM resulted in synergy with multiple vorinostat doses, whereas no synergy was seen with lower doses.
  • Importantly, sorafenib at 8 μM, but not lower doses, induced ER stress in these cell lines and thapsigargin or tunicamycin treatment recapitulated many, but not all, of the observed angiogenic gene responses to sorafenib.
  • In summary, sorafenib plus vorinostat potently inhibits the in vitro growth of RCC and NSCLC cell lines.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963311.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Epenetos AA, Kousparou C, Stylianou S: Inhibition of Notch and tumor regression. J Clin Oncol; 2009 May 20;27(15_suppl):e14623
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14623 Background: Notch signaling is an evolutionary-conserved pathway in vertebrates and invertebrates which is involved many developmental processes, including cell fate decisions, apoptosis, proliferation, and stem-cell self renewal.
  • Increasing evidence suggests that the Notch signaling pathway is frequently up regulated in many forms of cancer including acute T-cell lymphoblastic leukemia, cervical, prostate, lung, breast and others.
  • RESULTS: Our data show that ANTP/DN MAML fusion protein, TR4 contains signals for proper cell targeting, internalization and nuclear transport.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964214.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Fuchs E, Köstler W, Horvath R, Hudelist G, Kubista E, Attems J, Zielinski C, Singer CF: Use of the ErbB2/CEP17 ratio to predict prognosis and response to trastuzumab-based therapy in the metastatic breast cancer setting. J Clin Oncol; 2009 May 20;27(15_suppl):11110
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Significant differences in complete response (B/C: 16.9% vs C:44.4%), partial response (B/C: 20.2% vs. C: 33.3%) and progressive disease (B/C: 27% vs. 11.1%) were noted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963491.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Ayllon J, Banu E, Leviel F, Houillier P, Medioni J, Barrascout E, Oudard S, Maruani G: Bone markers in prostate cancer (PC) patients: Biologic criteria to identify patients at risk of developing distant metastases. J Clin Oncol; 2009 May 20;27(15_suppl):e16069
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16069 Background: Currently, there are no specific serum and/or urinary bone markers able to accurately identify PC patients with hormone-refractory disease and/or those with distant metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963065.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Quevedo F, Ashdown ML, Suman VJ, Robinson A, Kottschade LA, Kaur JS, Creagan ET, McWilliams RR, Markovic SN: Possible therapeutic reversal of immune suppression in patients with metastatic melanoma by timed delivery of temozolomide chemotherapy: A pilot study. J Clin Oncol; 2009 May 20;27(15_suppl):e20013
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: All 12 patients (median age 61; 4 female; 7 with M1c disease) exhibited oscillating CRP levels with an average periodicity of 7.8 days.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962562.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Herzog TJ, Vermorken JB, Pujade-Lauraine E, Li J, Bayever E, Gomez J, Yovine A, Monk BJ: Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone. J Clin Oncol; 2009 May 20;27(15_suppl):5550
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): Results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone.
  • : 5550 Background: OVA-301, an open-label, multicenter, randomized phase III study comparing the combination of T and PLD to PLD alone in 672 ovarian cancer patients, showed significant prolongation in Progression-Free Survival (PFS) and higher Objective Response (OR) in the combination arm (T-PLD) by three separate assessments, investigator assessment (IA), independent radiology (IR) and oncology review (IO).
  • The purpose of this analysis is to examine:.
  • 1) the impact of early changes in CA-125 over the subsequent best OR by RECIST;.
  • 2) the concordance between best OR determined by CA-125 and RECIST;.
  • 3) the value of CA-125 to predict radiological response.
  • METHODS: Tumor assessments by imaging and CA-125 were performed at baseline, and every 8 weeks during study in both arms.
  • Radiological tumor assessment, regardless of CA-125 changes, determined the study conduct.
  • Early CA-125 changes were those assessed at the first and second evaluation.
  • Analyses were based on "all randomized patients."
  • RESULTS: Response rate by RECIST (IR)/CA-125 was 28%/48% for T-PLD vs. 19%/33% for PLD.
  • The association between CA-125 and RECIST response was stronger for IA relative to IR/IO, with 79% concordance for both arms, 65% overall positive predictive value (PPV) and 89% negative predictive value (NPV) for IA and 74%/75% concordance, 46%/49% PPV and 93%/92% NPV for IR/IO.
  • Early CA-125 changes were assessed in 514 patients.
  • Early ≥25% CA-125 decreases in the first/second evaluation occurred in 85%/95% of RECIST responders in the T-PLD arm and in 81/82% responders treated with PLD.
  • CONCLUSIONS: The predictive value of CA-125 response was high and similar in both arms.
  • The addition of T to PLD resulted in superior efficacy in this patient population as assessed by IA, IR and IO, with a favorable trend for CA-125 response assessment.
  • RECIST response was preceded by a significant CA-125 decrease in a high proportion of patients.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962544.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Murakami F, Ogawa N, Yamazaki A, Sakurai S, Ishiya T, Katase K, Shimizu Y, Tanada S: Evaluation of preoperative positron emission tomography with computed tomography (PET-CT) for detecting lymph node metastasis in gynecologic carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):5593
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sensitivity of squamous cell carcinoma (SCC) were 35.7%, that of adenocarcinoma were 8.1%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962404.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Escofet X, Twine C, Roberts A, Dave B, Rawlinson C, Chan D, Crosby T, Robinson M, Lewis W: Prognostic significance of endoluminal ultrasound defined tumor volume (EDTV) in patients diagnosed with esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15519
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: One hundred and seventy-four consecutive patients (median age 64y, 128 m) underwent both CT and specialist EUS, and the maximum potential tumour cylinder volume (EDTV) was calculated using the formula πr<sup>2</sup>L (cylinder volume), where r = tumour thickness (cm) and L = total length of disease, including the position and level of both the primary tumour and proximal and distal lymph nodes (cm).
  • RESULTS: Survival was related to EUS T (p=0.013), EUS N (p=0.001), EUS M1a stage (p=0.004), EUS disease length (p=0.001), and EDTV (all patients <25cm<sup>3</sup>, p=0.001, surgical patients <40cm<sup>3</sup>, p=0.036).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962290.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Trejo Amador U, Granados Cosme JA, Ortiz Hernández L, Delgado Sánchez G: [Social Differences in Proper Detection of Cervical Uterine Cancer among Employees at a University in Mexico City]. Rev Esp Salud Publica; 2005 Jun 01;79:403-414
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Diferencias sociales de la detección oportuna de cáncer cérvico uterino en las mujeres trabajadoras de una Universidad de la Ciudad de México.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28272388.001).
  • [ISSN] 2173-9110
  • [Journal-full-title] Revista espanola de salud publica
  • [ISO-abbreviation] Rev. Esp. Salud Publica
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Cervical cancer / Inequalities / Life style / Mexico / Social conditions / Socioeconomic factors / Socioeconomic level.
  •  go-up   go-down


54. Kamoi K, Kawauchi A, Miki T, Aron M, Remer E, Haber G, Berger A, Crouzet S, Ricardo B, Gill I: Laparoscopic renal cryoablation: Risk factor analysis to predict oncologic outcomes with minimum 5-year follow-up. J Clin Oncol; 2009 May 20;27(15_suppl):5094
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the 69 patients with biopsy-proven renal cell cancer (median follow-up 81 mos; range 60-132 mos), 5-year overall, disease-specific, and disease- free survival was 75%, 92%, and 82%, respectively, while 10-year overall, disease-specific, and disease-free survival was 46%, 83%, and 79%, respectively.
  • Relative risk of patients who has a history of radical nephrectomy for RCC treatment was 4.1 (95% CIs, 1.2 to 13.4), and 5.4 (95% CIs, 1.2 to 27.7) for disease-free survival and disease-specific survival, respectively.
  • Disease-specific survival of 92% at 5-years and 83% at 10-years is possible.
  • Preceding radical nephrectomy for RCC treatment was the only independent predicting factor for both disease-free and disease-specific survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964294.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Rousseau M, Guevremont P, Chasen M, Spicer J, Eckert E, Alcindor T, Ades S, Ferri LE: The management of dysphagia in esophageal cancer patients undergoing neoadjuvant chemotherapy: Is invasive tube feeding required? J Clin Oncol; 2009 May 20;27(15_suppl):9613
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The management of dysphagia in esophageal cancer patients undergoing neoadjuvant chemotherapy: Is invasive tube feeding required?
  • : 9613 Background: The dysphagia commonly associated with esophageal cancer often interferes with patient tolerance of neo-adjuvant chemotherapy.
  • Surgical or endoscopic invasive tube feeding (ITF - gastroscopy/jejunostomy/stent) is a commonly employed strategy to maintain nutritional support however it can cause significant morbidity in its own right.
  • We sought to determine if a strategy of careful dietary counseling and appropriately-timed neoadjuvant chemotherapy can obviate the need for ITF.
  • METHODS: Pts undergoing neoadjuvant chemotherapy (TAX/CDDP/5FU Q3 weeks x3) for esophageal or GEJ adenocarcinoma at a single institution from 3/07-7/08 were identified from a prospective database.
  • All received dietary counseling and were closely monitored for signs/ symptoms of malnutrition with serial (baseline, after 1<sup>st</sup> cycle, pre-surgery) Body Mass Index (BMI), albumin, dysphagia scores (0 best - 4 worse), and quality of life (FACT-E).
  • We assessed the response of dysphagia and nutritional status to neoadjuvant treatment and the need for ITF.
  • Data presented as median (range) or mean (±SD), paired t-test or Wilcoxon signed ranks test determined significance.
  • RESULTS: 25 pts received neoadjuvant chemotherapy and significant dysphagia (score 2-4) was found in 14.
  • Dysphagia scores improved in all 14 (all results in Table 1 ), and 10/13 improved after the first cycle.
  • No patient required ITF.
  • QoL as assessed by the FACT-E improved in 13/14 patients.
  • A small decrease in BMI was noted, however serum albumin did not significantly decrease.
  • CONCLUSIONS: Appropriately timed neoadjuvant chemotherapy with a highly effective regimen rapidly restores normal swallowing, maintains nutritional status, and obviates the need for ITF in patients with significant dysphagia from esophageal adenocarcinoma.
  • [Table: see text] No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963863.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Casali PG, Stacchiotti S, Palassini E, Marrari A, Negri T, Morosi C, Messina A, Pastorino U, Gronchi A, Pilotti S: Evaluation of the antitumor activity of sunitinib malate (SM) in solitary fibrous tumor (SFT). J Clin Oncol; 2009 May 20;27(15_suppl):10571
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RTK biochemical analysis was performed in 3 patients of this series, in addition to a group of other patients with malignant SFT whose cryopreserved material was available.
  • RESULTS: Between 3 weeks and 3 months, 4 in 5 patients had a tumor response according to Choi's criteria (all with RECIST stable disease) .
  • In two, surgery of residual disease is planned, and downstream RTK signaling analysis will be performed on the specimen.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963778.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Wiechmann L, Jacks L, Patil S, Stempel M, Morrow M: Impact of molecular subtype on presenting characteristics of T1a,b tumors. J Clin Oncol; 2009 May 20;27(15_suppl):11111
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients overexpressing HER2 were significantly younger, had more nodal involvement, multicentric/multifocal (Multi) disease, extensive intraductal component (EIC), and lymphovascular invasion (LVI) (all p<0.0001).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963488.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Nakayama H, Kato Y, Tsuboi M, Okumura S, Daisaki H, Uehara H, Adachi S, Yoshimura M, Okada M: Value of FDG-PET/CT findings revised using an anthropomorphic body phantom for the evaluation of tumor malignancy grade in small-sized lung adenocarcinomas: A multicenter study. J Clin Oncol; 2009 May 20;27(15_suppl):7573
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7573 Background: The malignant behavior of small lung adenocarinomas (AD), which have been detected with increasing frequency recently, has not yet been clearly evaluated, and an understanding of this biological characteristic is vital for selecting the appropriate therapeutic strategy.
  • RESULTS: Examination of tumor aggressiveness based on the presence of lymphatic, vascular and pleural invasion, and of nodal metastasis, showed that maxSUV, BAC ratio, TDR, and GGO ratio, in the order, can reflect the malignancy grade.
  • MaxSUV and BAC ratio were also valuable prognostic predictors of the disease-free survival.
  • CONCLUSIONS: A higher maxSUV reflects an aggressive malignant behavior of cT1N0M0 ADs, independently of BAC component.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963381.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Di Lorenzo G, De Placido S, Cartenì G, Autorino R, Gonnella A, Rizzo M, Perdona S, Ricevuto E, Aieta M, Ewer M: Cardiovascular toxicity follwing sunitinib therapy in metastatic renal cell cancer: A multicenter analysis. J Clin Oncol; 2009 May 20;27(15_suppl):e16051
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiovascular toxicity follwing sunitinib therapy in metastatic renal cell cancer: A multicenter analysis.
  • We reviewed cardiac adverse events in patients with metastatic renal cell carcinoma (RCC) who underwent treatment with this agent.
  • Among these 17 patients, 12 (70.6%) also experienced left-ventricular systolic (LVEF) dysfunction; in all, 33 of the 175 patients (18.9%) developed some degree of cardiac abnormality, of which 12 were of classified as grade 3 LVEF dysfunction and/or congestive heart failure (CHF) (6.9%).
  • A significant univariate association for predictors of CHF were history of hypertension (p=0.008), history of coronary heart disease (p=0.0005) and prior treatment with an angiotensin converting enzyme inhibitor (ACE) (p= 0.04).
  • Multivariate analysis suggested that a history of coronary artery disease (OR 18, 95% CI, 4-160 p 0.005) and hypertension (OR 3, 95% CI, 1.5-80 p 0.04) were the only significant independent predictors of CHF.
  • CONCLUSIONS: Patients undergoing sunitinib, especially those with a previous history of hypertension and coronary heart disease, are at increased risk for cardiovascular events and should be monitored for exacerbations of their hypertension and for evidence of LVEF dysfunction during treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963002.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Armstrong GT, Pan Z, Ness K, Srivastava D, Robison LL: Temporal trends in cause-specific late mortality among five-year survivors of childhood cancer. J Clin Oncol; 2009 May 20;27(15_suppl):10004
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cause-specific mortality was categorized as death from recurrence/progression of primary disease, external causes, and non-recurrence/non-external causes (Non-Recur/Ext) (i.e., deaths from health conditions including sequelae of cancer therapy).
  • CONCLUSIONS: All-cause late mortality has improved with more recent eras, attributable to reduced rates of mortality from progression of primary disease (i.e., durable remission).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962548.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Papayannidis C, Iacobucci I, Soverini S, Paolini S, Cilloni D, Messa F, Pane F, Ottaviani E, Baccarani M, Martinelli G: Innovative phase I study of concomitant and consecutive treatment with dasatinib and MK-0457 in refractory Ph+ CML and ALL patients. J Clin Oncol; 2009 May 20;27(15_suppl):7080
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The third patient, in progression disease, received the 5 days MK-0457 schedule.
  • After one cycle of MK-0457, a complete recovery of the pulmonary disease and a complete hematologic response were obtained.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961473.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Christy CJ, Rishi M, Schwartz J, Grube BJ, Bossuyt V, Philpotts L, DiGiovanna MP, Tavassoli F, Lannin DR: Association between HER2/neu overexpression and calcifications in breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):579
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association between HER2/neu overexpression and calcifications in breast cancer.
  • : 579 Background: HER-2/neu overexpression is an important parameter that influences prognosis and treatment for breast cancer.
  • The purpose of this study is to explore the relationship between HER-2/neu overexpression and calcifications identified by either mammographic imaging or histologic examination.
  • METHODS: A retrospective review of the prospectively collected database was performed to evaluate the mammographic and histologic characteristics of all cases of invasive breast cancers diagnosed between 2003 and 2008.
  • HER-2/neu positivity was defined as either overexpression by FISH analysis or 3+ staining on immunohistochemistry.
  • RESULTS: Of 502 invasive cancers, 165 (33%) had calcifications on mammography and 337 (67%) did not.
  • HER-2/neu positivity was found in 63 (38%) of the calcification cases and 40 (12%) of the non-calcified cases (p < 0.001).
  • This association persisted across all age groups and races and was independent of tumor size, nodal status, or hormone receptor status.
  • Calcifications seen histologically also correlated with HER-2/neu overexpression, but the relationship was more complex.
  • Among 155 cases with histologic calcifications seen within a ductal intraepithelial neoplasia (DIN) component, there were 45 (29%) that were HER-2/neu positive, compared with 67/414 (16%) that did not have calcifications within DIN (p < 0.001).
  • If the calcifications were only within invasive tumor, the rate of HER-2/neu overexpression was less, 9/63 (14%).
  • Univariate analysis demonstrated that tumor grade, necrosis, lymphovascular invasion and hormone receptor negativity were significantly associated with HER-2/neu overexpression (all p < 0.01).
  • Multivariate logistic regression showed only the following factors to be significantly associated with HER-2/neu overexpression: grade of invasive tumor, presence of necrosis, progesterone receptor negativity in either the invasive or the in situ component, and mammographic calcifications.
  • CONCLUSIONS: Recognition of the strong association between HER-2/neu overexpression and mammographic calcifications may have clinical usefulness and could lead to a better understanding of the underlying tumor biology of this important tumor marker.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960749.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Lu Q, Zhao A, Shen L: Preoperative transcatheter arterial chemoembolization (TACE) and chemotherapy for hepatic colorectal metastases: Impact on hepatic histology and postoperative outcome. J Clin Oncol; 2009 May 20;27(15_suppl):e15090
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative transcatheter arterial chemoembolization (TACE) and chemotherapy for hepatic colorectal metastases: Impact on hepatic histology and postoperative outcome.
  • : e15090 Background: The objective was to evaluate the effect of preoperative administration of TACE and chemotherapy on hepatic injury and on postoperative outcome in patients with colorectal liver metastases (CRM) Methods: Seventy seven patients underwent hepatic resection for CRM between January 1999 and December 2007 were evaluated.
  • Pathologic review of the non-tumorous liver was performed using established criteria for steatosis, steatohepatitis, and sinusoidal dilation.
  • The effect of two different treatment and hepatotoxicity on postoperative outcome was analyzed.
  • RESULTS: 40 patients (51.9%) received no preoperative treatment, where 27 patients (35.0%) received preoperative chemotherapy, 10 patients (12.9%) performed TACE before resection.
  • The median duration of TACE group was 4.5 months (range, 1-6 months), where the median duration of chemotherapy group was 5 cycles (range, 2-9 cycles).
  • Chemotherapy regimen consisted of oxalipaltin plus FU (29.9%), or irinotecan plus FU (5.2%).
  • On pathologic analysis, 36 patients (46.7%) had steatosis, 24 (31.1%) had sinusoidal dilation, and 8 (10.3%) had steatohepatitis.
  • TACE was associated with steatosis, steatohepatosis and postoperative complication, when compared with no chemotherapy (all p<0.05).Among chemotherapy group,Oxaliplatin was associated with steatohepatitis compared with no preoperative treatment (13.0% v 0%, respectively; p<0.05).
  • Irinotecan was associated with steatohepatitis compared with no preoperative treatment (50% v 0%, respectively; p=0.0006).
  • Patients with preoperative chemotherapy had increased steatohepatitis compared with no treatment group (18.5% v 0%, respectively, p=0.0008), the postoperative morbility rate in preoperative chemotherapy (25.9%) was double that of the no-chemotherapy (12.5%), but this difference was not statistically significant (p=0.20).
  • Preoperative chemotherapy was also not associated with 90-day mortality.
  • CONCLUSIONS: Preoperative TACE treatment may cause pathological liver injury, and increase postoperative morbility after hepatic surgery.
  • The standard preoperative chemotherapy regimen with Oxaliplatin or Irinotecan may increase steatohepatis.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964609.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Wulfing C, Herrmann E, Trojan L, Schrader A, Becker F, Stähler M, Haferkamp A, Legal W, Brenner W, Hartmann A, German Papillary Renal Cancer Study Group: Independent validation of the 2002 UICC TNM staging system for papillary renal cell carcinoma in a multicenter cohort. J Clin Oncol; 2009 May 20;27(15_suppl):5092
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent validation of the 2002 UICC TNM staging system for papillary renal cell carcinoma in a multicenter cohort.
  • : 5092 Background: Papillary renal cell carcinoma (pRCC) is the second most malignant histologic subtype in nephrectomy specimens.
  • Synchronous distant metastases in the entire group occurred in 58 (8.7%) patients and 69 (11.2%) others developed metastatic disease during follow-up.
  • Patients with ≥pT3 were at high risk for metastases (50.6%), while metastatic disease associated with ≤pT2 tumors occurred in 7.8% (p < 0.0001).
  • Once metastatic disease was present, prognosis was poor (5-year CSS: 7.2%).
  • Clinical and radiologic follow-ups should be offered in frequent intervals to patients with venous thrombus and/or locally advanced disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964296.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Nadeem A, Wanebo H, Shrayer D, Hazelwood S, Resnick M: Effect of the apoptosis signal ceramide (C6) on antitumor activity of chemotherapeutic agents in SCID mice. J Clin Oncol; 2009 May 20;27(15_suppl):e14642
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of the apoptosis signal ceramide (C6) on antitumor activity of chemotherapeutic agents in SCID mice.
  • : e14642 Introduction: The ceramides are a major signaling pathway for apoptosis in cells undergoing stress or exposure to chemotherapy.
  • We have demonstrated synergistic anti-tumor effects of combining C6 ceramide with paclitaxel, doxorubicin and cisplatin and are currently addressing the question; does C6 augment activity of all the major classes of drugs?
  • Backround: Currently the in vivo anti-tumor effects of C6 with oxaliplatin and Gemcitabine.
  • METHODS: Invivo experiments SCID/Beige/Taconic male mice inoculated S.C. with 2X106 L3.6 pancreatic cells were treated 4 days post tumor implant with trice weekly (3x/wk) intraperitoneal (IP) injections of paclitaxel (P) 3.0 m/kg, oxaliplatin (OX) 2.5 mg/kg, cisplatin (CP) 2.5 mg/kg, Gemcitabine (Gem) 10 mg/kg with/without ceramide 10 mg/kg.
  • Mice were observed for 6 weeks and were autopsied when near death. (All controls died by 3<sup>rd</sup> week).
  • Maximum tumor volume, tumor weight; body weight and survival were recorded.
  • RESULTS: Combination with C6 ceramide augmented the tumor reduction obtained by chemotherapy alone by 57% (while preserving body weight), and increased 6 week survival from 0% (Chemotherapy alone) to 60% with combined therapy.
  • Mean survival was increased from 25 to 37 days.
  • Although short term immunohistochemical studies suggested enhanced apoptosis and increased caspase 3 production by ceramide combinations it may actually be independent of capase activation and mitochondrial activation.
  • CONCLUSIONS: Combination therapy with the apoptotic signal C6 ceramide significantly enhanced the anti-tumor effects of the anti microtubule, alkylating Paclitaxel a DNA interculating antibiotic (doxorubicin) the alkylating/DNA adducting agents (cisplatin, oxaliplatin) and an anti metabolite (gemcitabine) suggesting generation of broad based apoptotic signals which interact with major cancer drug classes (tested).
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964231.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. von Mehren M, Chu Q, Alcindor T, Townsley C, Thallury S, MacAlpine K, Wright JJ, Oza A: Early results of a PMH Phase II Consortium trial of AZD0530 in advanced soft tissue sarcoma (STS). J Clin Oncol; 2009 May 20;27(15_suppl):10579
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Src kinases play a role in tumor cell migration, invasion and metastasis as well as being part of the signaling cascade for angiogenesis and growth factors.
  • METHODS: The study utilized a Simon Two stage design with the primary endpoint be objective tumor response + prolonged stable disease rate (defined as partial/complete response by RECIST, or stable disease >4 months).
  • Patients with measurable advanced STS with up to one prior chemotherapy for metastatic disease were eligible for study participation following informed consent.
  • Nine discontinued therapy for progressive disease, 2 for toxicity and 1 patient request.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963760.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Pavoni-Ferreira PC, Petrilli AS, Alves MT, Jesus-Garcia Filho R, Toledo SR: Angiogenic biomaker study in osteosarcoma. J Clin Oncol; 2009 May 20;27(15_suppl):e21507
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Angiogenic biomaker study in osteosarcoma.
  • : e21507 Background: This study represents a prospective assessment of angiogenesis genes mRNA expression in tumors and blood from patients treated with pre- and post-operative Brazilian osteosarcoma protocol (GCBTO 2006) that introduce metronomic chemotherapy (anti-angiogenic) in order to try to increase survival of osteosarcoma patients.
  • METHODS: Tumor samples from 27 patients were analyzed before and after chemotherapy to determine VEGFA, VEGFR1, VEGFR2, PDGFC, SDF1 and TSP1 genes expression profile by Quantitative Real Time PCR.
  • Also, blood samples of these patients were investigated pre- and post-chemotherapy and at the end of high-dose chemotherapy trying to evaluate potential for proangiogenic factors and antiangiogenic factor (TSP1) which could be used to monitor treatment activity.
  • RESULTS: Of all six genes studied pre- and post- chemotherapy, in tumor samples, only SDF1 and VEGFR2 were underexpressed.
  • SDF1 gene has the lowest expression at all.
  • In tumor samples, TSP1 and VEGFA expression was higher than SDF1, VEGFR2 and PDGFC expression in biopsies and surgeries (P=0.001).
  • VEGFR1 expression was higher than VEGFR2 expression (P=0.001).
  • PDGFC and VEGFR1 overexpression were associated with necrosis grade I and II (Huvos score) (P=0.005).
  • VEGFA and TSP1 were overexpressed in 96% and 92% of surgery samples, respectively.
  • In blood samples from biopsy, surgery and end of treatment there were no statistically significant changes in the marker genes expression.
  • CONCLUSIONS: The study suggests an association between PDGFC and VEGFR1 overexpression and lower grade necrosis.
  • TSP1 and VEGFA were the most expressed genes in all tumor samples but TSP1 was lower than VEGFA in biopsies and VEGFA was lower than TSP1 in surgery (P=0.001).
  • Although VEGFR2 is the primary receptor of VEGF, VEGFR1 was the most expressed VEGF receptor.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963397.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Merrell RT, Lachance DH, Anderson SK: Seizures in patients with glioma treated with phenytoin and levetiracetam. J Clin Oncol; 2009 May 20;27(15_suppl):e13020
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Seizures in patients with glioma treated with phenytoin and levetiracetam.
  • : e13020 Background: Seizures are common in patients with glioma.
  • Phenytoin, traditionally used for these patients, can be associated with intolerable side effects and potentially alters the metabolism of chemotherapeutic agents.
  • Levetiracetam has more favorable pharmacokinetics facilitating ease of use with fewer side effects and is nonenzyme inducing.
  • We compare seizure outcomes and side effects in patients with glioma treated with phenytoin and levetiracetam monotherapy.
  • METHODS: Retrospective analysis of consecutive patients with glioma.
  • Subjects had at least one clinical seizure and had to be followed for 6 months.
  • Seizure outcomes and side effects were compared between cohorts treated with phenytoin or levetiracetam.
  • Seizure outcomes were measured by time to second seizure and seizure frequency.
  • RESULTS: 76 patients (34 female) with pathologically proven glioma and seizures were identified, 25 treated with phenytoin and 51 with levetiracetam.
  • 64% had grade 4 astrocytoma.
  • There was no difference in seizure outcome between the phenytoin and levetiracetam groups when comparing time to second seizure (p = 0.584), second seizure rates (p = 0.462), and average seizures per month (p = 0.776).
  • When adjusting for age, gender, type of seizure, type of glioma, and dosage using univariate and multivariate models there were no differences between the treatment groups and none of these covariates were statistically significant for explaining the second seizure rates between treatment groups (all p values >0.05).
  • The incidence of side effects in the levetiracetam group was 5.9% versus 20% in the phenytoin group (p = 0.106).
  • Additionally, 36.0% of the patients in the phenytoin group had dose adjustments not related to breakthrough seizures compared to only 9.8% in the levetiracetam group (p = 0.010).
  • CONCLUSIONS: In this study, glioma patients treated with levetiracetam had similar seizure control as patients treated with phenytoin.
  • Patients treated with levetiracetam experienced fewer side effects and required fewer non seizure related dose adjustments than patients treated with phenytoin.
  • Levetiracetam is a safe, effective, and preferred alternative for seizure management in patients with glioma.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962817.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Pavlakis N, Hirsh V, Reck M, Wu Y, Dansin E: MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC). J Clin Oncol; 2009 May 20;27(15_suppl):e19003
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MO19390 (SAiL): Incidence of thromboembolic events and congestive heart failure with first-line bevacizumab (Bv)-based therapy in advanced non-small cell lung cancer (NSCLC).
  • METHODS: Key eligibility criteria were untreated locally advanced, metastatic or recurrent non-squamous NSCLC, ECOG PS 0-2, tumor not abutting major blood vessels, no uncontrolled HTN (systolic >150mmHg and/or diastolic >100mmHg) or active cardiovascular disease at baseline.
  • Non-progressors proceeded to receive Bv until disease progression.
  • Pts (%) were: male 60.1; stage IIIB/IV 19.5/80.5 (no data for 3 pts); adenocarcinoma/large cell/other 85.8/7.1/7.1; ECOG PS 0/1/2 38.1/56.1/5.8.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962518.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Yeo W, Goh B, Le Tourneau C, Green SR, Chiao JH, Siu LL: A phase II randomized study of oral seliciclib in patients with previously treated nasopharyngeal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):6026
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligible patients must be ≥18 years with previously treated NPC or other incurable solid tumors; must have measurable disease according to RECIST, ECOG 0-1, and adequate bone marrow, hepatic and renal function.
  • Majority of stable disease occurred in NPC patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962434.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Gilbert J, Lee J, Argiris A, Feldman L, Haigentz M, Burtness B, Forastiere A, Eastern Cooperative Oncology Group: Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol; 2009 May 20;27(15_suppl):6020
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized trial of bortezomib (B) plus irinotecan (I) or B with addition of I at progression in recurrent (R) or metastatic (M) squamous cell carcinoma of the head and neck (SCCHN) (E1304): A trial of the Eastern Cooperative Oncology Group.
  • : 6020 Background: B, inhibits activation of NF- κβ and inhibits growth of SCCHN cell lines.
  • To date, RR low but prolonged stable disease noted in some pts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962416.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Wang XS, Williams LA, Johnson VE, Mao L, Krishnan S, Liao Z, Mobley G, Cleeland CS: Association of sTNF-R1 and the development of treatment-related symptoms in patients undergoing concurrent chemoradiation therapy for colorectal or esophageal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):3041
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum samples were tested weekly during therapy for changes in concentration levels of inflammatory cytokines (interleukin [IL]-6, IL-8, IL-10, IL-1 receptor antagonist [IL-1RA], vascular endothelial growth factor [VEGF], and soluble tumor necrosis factor receptor type 1 [sTNF-R1]) via enzyme-linked immunosorbent assay (ELISA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961980.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Borthakur G, Chiao J, Kantarjian H: A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS. J Clin Oncol; 2009 May 20;27(15_suppl):7021
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 7021 Background: Sapacitabine is a novel nucleoside analogue with a unique ability to cause irreparable single-strand DNA breaks and induce G2 cell cycle arrest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961383.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Grimley PM, Matsuno R, Anderson WF: Population profiles of extra-ovarian and ovarian serous adenocarcinomas: Comparisons with grade stratification. J Clin Oncol; 2009 May 20;27(15_suppl):e16506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Incidence rates (IR) stratified by grade were compared by year or age of diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960765.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Ocvirk J, Rebersek M: Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream. J Clin Oncol; 2009 May 20;27(15_suppl):e15087
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of cetuximab-associated cutaneous side effects using topical aplication oh vitamin K1 cream.
  • : e15087 Background: The EGFR-targeting monoclonal antibody cetuximab has been licensed by the EMEA in combination with chemotherapy for the treatment of 1<sup>st</sup> line metastatic colorectal cancer (mCRC) patients (pts) whose tumors have KRAS wild type status.
  • The major side effects of cetuximab are cutaneous reactions (approx.
  • 80% of pts.) predominantly consisting of an acne- like rash 60-100%, but also including pruritus, dry skin (35%), desquamation, hypertrichosis and nail disorders (10-40%).
  • If not properly managed, they have the potential to cause dose reductions and delays, which may in turn impact on treatment efficacy.
  • The aim of our study was to determine the efficacy of topical vitamin K1 cream in pts with cutaneus side effects caused by cetuximab therapy.
  • METHODS: Between January 2007 and August 2008, 79 pts with mCRC were treated with weekly cetuximab in combination with chemotherapy.
  • Topical use of a cream containing urea and 0.1% vitamin K1 was applied when an acne-like rash (NCI CTCAE version 3) appeared .
  • Pts were monitored weekly for at least 12 weeks.
  • RESULTS: Sixty nine patients developed an acne-like rash after a median of 1.2 weeks after first cetuximab administration (range 1- 4), 20 pts grade 3, 38 grade 2 and 11 grade 1.
  • Twice-daily application of vitamin K1 cream resulted in a gradual decrease in cutaneous toxicity.
  • Median time to improvement (all toxicity grades) was 1.2 weeks and 2.3 weeks to a down-staging of the rash by at least 1 grade.
  • Dose reduction of cetuximab was necessary for only 5 of the 20 pts with grade 3 toxicity.
  • No dose reductions or treatment delays were needed for any patient with grade 1 or 2 cutaneous toxicity.
  • Topical clindamycin was used concomitantly in 12/20 and 2/38 pts with grade 3 and grade 2 reactions respectively.
  • No toxicity was associated with the topical use of vitamin K1cream.
  • CONCLUSIONS: This study demonstrated the efficacy of topically applied vitamin K1 containing cream in the management of cetuximab-induced acne-like skin rash.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964556.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Breunis H, Timilshina N, Tomlinson G, Naglie G, Tannock I, Fleshner N, Krahn M, Duff Canning S, Warde P, Alibhai S: Declines in physical function from androgen deprivation therapy (ADT) in men with nonmetastatic prostate cancer: A matched cohort study. J Clin Oncol; 2009 May 20;27(15_suppl):9526
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Declines in physical function from androgen deprivation therapy (ADT) in men with nonmetastatic prostate cancer: A matched cohort study.
  • : 9526 Background: Although prolonged use of ADT is hypothesized to adversely affect physical function, few studies have examined this relationship longitudinally using objective measures of physical function.
  • METHODS: Men age 50+ with non-metastatic prostate cancer (PC) starting continuous ADT were enrolled in this prospective longitudinal matched cohort study.
  • Physical function was assessed with the six-minute walk test (6MWT), grip strength, and the Timed Up and Go (TUG) test, representing endurance, upper extremity strength, and lower extremity strength, respectively.
  • Self-reported physical function was measured with the Medical Outcomes Study SF-36.
  • Assessments were done at baseline, 3 months, 6 months, and 12 months.
  • Two control groups, matched on age, education, and baseline function were also enrolled.
  • One control group had PC but did not receive ADT, and the other group did not have PC.
  • Linear mixed effects regression models were fitted adjusting for baseline covariates.
  • RESULTS: 85 patients on ADT, 86 PC controls, and 86 healthy controls were enrolled.
  • All 3 groups were similar in age (mean age 69.1 y, range 50-87) and physical function (all ANOVA p>0.05).
  • The 6MWT distance improved in both control groups (p=0.05 and 0.05 for PC and healthy controls, respectively) but remained stable in the ADT group (p=0.96)).
  • Grip strength declined in the ADT group (p=0.04), remained stable in the PC control group (p=0.31), and improved in the healthy control group (p=0.008).
  • TUG scores remained stable over time and across groups (p>0.10).
  • SF-36 physical function declined in the ADT group (p<0.001) but increased in both control groups (p<0.001).
  • Negative effects on outcomes were noted within 3-6 months of starting ADT and were larger with older age.
  • CONCLUSIONS: Endurance, upper extremity strength, and self-reported physical function are affected within 3-6 months of starting ADT, particularly in older men.
  • Declines persist at 12 months after adjustment for baseline function and covariates.
  • Exercise intervention studies to counteract these losses are warranted.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964515.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Fan L, Reeve E, Mohile S: The impact of cancer on geriatric syndromes in older Medicare beneficiaries. J Clin Oncol; 2009 May 20;27(15_suppl):9506
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Adjusting for possible confounders including age and comorbidity, subjects with any diagnosis of cancer were more likely to have hearing trouble (OR 1.31, 95% CI: 1.10-1.56), incontinence (OR 1.35, 95% CI: 1.16-1.57), falls (OR 1.18, 95% CI: 1.05-1.31), depression (OR 1.19, 95% CI: 1.03-1.39), and osteoporosis (OR 1.20, 95% CI: 1.06-1.35).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964461.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Heist RS, Fain J, Chinnasami B, Khan W, Molina J, Brainerd V, Leopold L, Lynch T: A phase I/II (P1/P2) study of AT-101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum-containing first-line chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):8106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I/II (P1/P2) study of AT-101 in combination with topotecan (T) in patients with relapsed or refractory small cell lung cancer (SCLC) after prior platinum-containing first-line chemotherapy.
  • METHODS: Pts ≥18 years of age, PS 0-1, with relapsed or refractory SCLC after first line chemotherapy with measurable disease per RECIST were eligible.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964282.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Schrader AJ, Rauer-Bruening S, Olbert PJ, Hegele A, Rustemeier J, Hofmann R: Incidence and long term prognosis of papillary renal cell carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16020
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and long term prognosis of papillary renal cell carcinoma.
  • : e16020 Background: Papillary renal cell carcinoma (pRCC) represents the largest subgroup of non clear-cell kidney cancer.
  • In this study we assessed tumour characteristics and long-term prognosis of patients with pRCC in comparison with conventional clear-cell cancer (ccRCC).
  • RESULTS: Both groups pRCC and ccRCC were alike concerning age, body mass index, and the incidence of regional lymph node or distant metastasis at diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962984.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Jotte R, Conkling P, Reynolds C, Klein L, Fitzgibbons JF, McNally R, Renschler M, Oliver JW: Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy. J Clin Oncol; 2009 May 20;27(15_suppl):8028
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962841.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


81. Di Fabio F, Pinto C, Rojas Llimpe F, Castellucci P, Fanti S, Mutri V, Giaquinta S, Di Tullio P, Pini S, Compagnone G, Martoni A: Early predictive value of 18F-FDG-PET assessment in advanced esophagogastric junction and gastric cancer patients treated with cetuximab-containing therapy. J Clin Oncol; 2009 May 20;27(15_suppl):e15601
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Five pts (10.2%) had FDG non- avid tumor (all pts with signet cell carcinoma).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Von Gruenigen VE, Frasure H, Fusco N, Eldermire E, Eaton S, Waggoner S: A double-blind randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin hydrochloride-related palmar-plantar erythrodysesthesia. J Clin Oncol; 2009 May 20;27(15_suppl):5594
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A double-blind randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin hydrochloride-related palmar-plantar erythrodysesthesia.
  • : 5594 Background: To compare the efficacy of pyridoxine versus placebo in the prevention of palmar-plantar erythrodysesthesia (PPE) and on quality of life (QOL) in patients treated with pegylated liposomal doxorubicin hydrochloride for ovarian, breast, or endometrial cancer.
  • METHODS: All patients received pegylated liposomal doxorubicin hydrochloride 40 mg/m2 IV q 4 weeks over 1 hour every 28 days for a maximum of 6 cycles.
  • Patients received pyridoxine 100 mg (group A) by mouth or placebo (group B) twice daily.
  • Nurses conducted standard PPE education for all patients.
  • Patients with Grade 2 or 3 PPE that persisted despite dose reductions/delays were unblinded, and were given pyridoxine if taking placebo.
  • Patients completed the Functional Assessment of Cancer Therapy (FACT) assessment tool.
  • Analyses were conducted by group and comparisons were also made between patients who experienced grade 2/3 PPE versus grade 0/1.
  • Chi-square or Fisher's exact test were used.
  • RESULTS: Thirty-four patients were enrolled with 18 randomized to group A and 16 to group B.
  • Mean age was 64 years (SD=9.6; range 45-81 years).
  • Five patients (group A, 3; group B, 2) were unevaluable (due to pegylated liposomal doxorubicin hydrochloride reaction during first chemotherapy cycle).
  • Overall 15/29 (52%) patients had incidence of PPE (all grades), with 10/29 (34%) having grade 2/3 events (no grade 4 events observed).
  • In group A, 8/15 (53%) patients had a PPE event and 7/14 (50%) in group B; p=0.857.
  • For grade 2/3 events, there was no difference as 6/15 (40%) occurred in group A and 4/14 (29%) in group B; p=0.70.
  • There were no differences in global or domain QOL scores between those patients with Grade 2/3 PPE versus Grade 0/1.
  • Less than half [4/10 (40%)] of patients with Grade 2/3 PPE reported being bothered by side effects of pegylated liposomal doxorubicin hydrochloride treatment.
  • CONCLUSIONS: As administered in this study, pyridoxine did not prevent PPE in patients treated with pegylated liposomal doxorubicin hydrochloride.
  • Quality of life differences were not observed; however, not all patients with PPE reported being bothered by side effects of pegylated liposomal doxorubicin hydrochloride treatment.
  • Pyridoxine is not indicated for prevention of PPE during chemotherapy.
  • [Table: see text] [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962403.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Wilgenhof S, Van Nuffel AM, Benteyn D, Pierret L, Heirman C, De Coninck A, Van Riet I, Bonehill A, Thielemans K, Neyns B: Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in patients with advanced melanoma. J Clin Oncol; 2009 May 20;27(15_suppl):9024
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic vaccination with an autologous TriMix-Dendritic cell vaccine combined with sequential interferon alfa-2b in patients with advanced melanoma.
  • Out of the 11 pts without evaluable disease, 2 had a local recurrence (salvaged by surgery).
  • After a mFU of 7.8 mths (range 4.3-13.7) all pts remain disease-free.
  • Out of the 13 pts with measurable disease, BOR (RECIST) was 8 SD and 5 PD; 1 pt with initial PD subsequently obtained a PR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962374.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Wagner JL, Warneke C, Bedrosian I, Mittendorf E, Babiera G, Kuerer H, Hunt K, Yang W, Sahin A, Meric-Bernstam F: Effect of modest delays in primary surgical treatment on progression of tumor size in breast cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):622
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: There is no evidence that time lapse from initial imaging to surgical intervention leads to significant changes in tumor size thus allowing patients to complete preoperative workup and planning without significant clinical disease progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961425.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Moroney JW, Coleman RL, Hong DS, Wheler JJ, Ng C, Bodurka DC, Falchook G, Naing A, Helgason T, Kurzrock R: A phase I trial of liposomal doxorubicin (D), bevacizumab (A), and temsirolimus (T) in advanced malignancy. J Clin Oncol; 2009 May 20;27(15_suppl):e13508
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1 patient had stable disease.
  • One of the patients with endometrial cancer and extensive intra-abdominal disease who showed rapid tumor regression (≥ 25% decrease at 2 months) developed an entero-colonic fistula, and chose hospice care.
  • Patients with intra-abdominal disease who experience rapid tumor regression may be at risk for fistula formation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961272.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Onishi T, Singh V, Rosenzweig M, Sereika S, Brufsky AM: Long-term treatment with intravenous bisphosphonates in metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):1035
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term treatment with intravenous bisphosphonates in metastatic breast cancer (MBC).
  • : 1035 Background: Intravenous bisphosphonates (IV BPs) are safe and effective in reducing skeletal related events in MBC.
  • The effects of IV BPs after 24 months of therapy are unknown.
  • The incidence of osteonecrosis of the jaw (ONJ) and renal insufficiency (RI) among women with MBC receiving >= 24 months of IV BPs is also poorly defined.
  • We studied the long term effect of IV BPs in a cohort of women with MBC.
  • METHODS: We maintain an ongoing prospective database of >600 women with MBC diagnosed and treated at our institution from January 1999.
  • A long-term cohort (LTC) of 159 women with metastatic breast cancer to bone treated for >= 24 months with pamidronate (n = 9), zoledronic acid (n = 110), or both (n = 40) was identified.
  • A control cohort (CC) of 62 women with MBC to bone treated with IV BPs for 12-23 months was also identified.
  • RI was defined as an increase in serum creatinine (scr) of > 0.5 mg/dl or an absolute level of scr >1.5mg/dl; ONJ was diagnosed by dental consultation.
  • RESULTS: Median follow-up of the LTC was 39 months (range 24-99) months.
  • Median overall survival in this cohort was 43 months (range 24-114).
  • The vast majority of women in the LTC (140/159, 88.1%) continued to receive IV BPs at standard dose every 3-4 weeks.
  • The incidence of ONJ in the LTC was 6/159 (3.8%), after a mean 42.2 treatment cycles, with a median time to ONJ of 44 months.
  • Three of six patients with ONJ (50%) underwent surgical resection, and 3/6 (50%) were managed conservatively, and 3/6 (50%) resumed IV BPs after a mean 12 month hold.
  • The incidence of RI (all pts had baseline scr < 1.4 mg/dl) in the LTC was 19/159 (11.9%), occurring after a mean 43.4 treatment cycles, with a median time to RI of 43 months.
  • Eleven of 19 patients (57.9%) recovered to baseline scr and 7/19 (36.7%) patients showed partial recovery.
  • Seventeen of 19 patients (89.4%) were able to resume therapy after temporary discontinuation, decreasing the dose, or increasing the interval of the IV BP.
  • Incidence of ONJ in the CC was 1/62 (1.6%) and RI in the CC was 6/62 (9.7%).
  • CONCLUSIONS: Long term (>=24 month) IV BP use in MBC is well tolerated and safe, with relatively low incidence of ONJ and RI.
  • Most patients were able to resume IV BP therapy after a therapy hold without further complication.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961083.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Duvic M, Forero-Torres A, Foss F, Olsen E, Pinter-Brown L, Kim Y: Long-term treatment of CTCL with the oral PNP inhibitor, forodesine. J Clin Oncol; 2009 May 20;27(15_suppl):8552
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 8552 Background: Forodesine is a potent inhibitor of purine nucleoside phosphorylase (PNP) that leads to T-cell selective intracellular accumulation of dGTP, resulting in apoptosis.
  • Six discontinued treatment (median time on treatment 440 days): 4 for progressive disease, 1 withdrew consent, and 1 due to an adverse event (Diffuse Large B-cell Lymphoma).
  • Five of 9 subjects had a response (2 with complete response, 3 with partial response, and 4 with stable disease).
  • Grade 3 or higher related AEs were experienced by 2 of 9 subjects (Diffuse Large B-Cell Lymphoma as previously mentioned and peripheral edema).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960987.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Springer B, Danoff J, Levy E, Stout N, Pfalzer L, McGarvey C, Gerber L, Soballe P: Functional recovery after surgery in patients with breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20539
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During post BC treatment visits, appropriate physical therapy was provided, and if there was a diagnosis of lymphedema, a light-grade compression garment was fitted.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960969.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Rodrigues MJ, Wassermann J, Albiges-Sauvin L, Stevens D, Brain E, Delaloge S, Mathieu M, Guillot E, Vincent-Salomon A, Cottu PH: Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study. J Clin Oncol; 2009 May 20;27(15_suppl):517
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas: A joint AERIO/REMAGUS study.
  • : 517 Background: Trials have shown benefit of adjuvant trastuzumab (TZM) for node-positive (N+) or supra-centrimetric HER-2+ breast carcinomas.
  • There are limited data concerning infra-centimetric HER-2+ invasive breast carcinomas (InfraHER-2).
  • These tumors are being recognized as a high-risk group among all T1a/b tumors.
  • METHODS: Retrospective multicenter series from 2000 to 2008 of infra-centimetric HER-2+ invasive breast carcinomas (InfraHER-2).
  • Tumors with ≥80% of ductal carcinoma in situ, multifocal and metastatic tumors were excluded.
  • RESULTS: 96 cases have been evaluated, 75 were node negative (N- InfraHER-2).
  • All patients had surgery.
  • 57% (n = 43) had a sentinel lymph node procedure.
  • 73% (n = 55) had a local irradiation and 36 a tumor bed boost.
  • Nodal irradiation of internal mammar and infra/supraclavicular regions was done in 20% and 17% respectively.
  • 44% (n = 33) had chemotherapy (CT), almost all (31) were associated to TZM.
  • Anthracycline-based (A), taxane-based (T) and A/T combinations were chosen for 54%, 4% and 42% respectively.
  • One patient developed myocardial infarction after A resulting in heart failure; 2 had a transient left ventricular ejection fraction decrease below 50% after TZM.
  • Decision of adjuvant CT was associated (all p < 0.05) with hormonal receptors (HR) negative status, Elston-Ellis grade (EE) 2/3 and high mitotic index (MI) while patients with HR+/low MI tumors were rarely treated (p < 0.001).
  • 32/39 HR+ patients received hormonotherapy (80%); 21 received aromatase inhibitors, 6 tamoxifen and 5 LHRH agonists.
  • With a 25 months median follow-up, there was no invasive recurrence in TZM treated patients.
  • 3 of the 44 patients treated without TZM nor CT (7%) had local or metastatic recurrence including one fatal; they had initially HR- EE 2/3 T1b tumors.
  • CONCLUSIONS: In our practice, decision of TZM-based therapy for InfraHER-2 N- tumors is associated with high-risk profile.
  • Indeed, N- InfraHER-2 tumors may have a significant risk of recurrence which could be avoided by adjuvant TZM.
  • Patients with N- InfraHER-2 tumors should be included in HER-2-targeted adjuvant trials.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960805.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Randall-Whitis L, Burger RA, Sill M, Monk BJ, Buening Ccrc B, Sorosky JI: Predictive value of serum CA125 levels in women with persistent or recurrent epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) treated with bevacizumab (Bev) on a Gynecologic Oncology Group (GOG) phase II trial. J Clin Oncol; 2009 May 20;27(15_suppl):e16505
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary objective of this study was to determine the proportion of pts treated with bevacizumab on a phase II clinical trial with stable disease by RECIST who demonstrated disease progression (pgrn) as assessed by modified GCIG CA125 criteria.
  • Pts were removed from therapy/evaluation for disease prgn by RECIST, toxicity, or by subject request.
  • CONCLUSIONS: Serum CA125 levels were a useful marker of progression in some pts treated on this trial; however, some pts received clinical benefit from continued therapy in spite of indications of disease prgn by CA125.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960764.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Kiers HA: Properties of and Algorithms for Fitting Three-Way Component Models with Offset Terms. Psychometrika; 2006 Jun;71(2):231-256
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Properties of and Algorithms for Fitting Three-Way Component Models with Offset Terms.
  • : Prior to a three-way component analysis of a three-way data set, it is customary to preprocess the data by centering and/or rescaling them.
  • Harshman and Lundy (1984) considered that three-way data actually consist of a three-way model part, which in fact pertains to ratio scale measurements, as well as additive "offset" terms that turn the ratio scale measurements into interval scale measurements.
  • They mentioned that such offset terms might be estimated by incorporating additional components in the model, but discarded this idea in favor of an approach to remove such terms from the model by means of centering.
  • Then estimates for the three-way component model parameters are obtained by analyzing the centered data.
  • In the present paper, the possibility of actually estimating the offset terms is taken up again.
  • First, it is mentioned in which cases such offset terms can be estimated uniquely.
  • Next, procedures are offered for estimating model parameters and offset parameters simultaneously, as well as successively (i.e., providing offset term estimates after the three-way model parameters have been estimated in the traditional way on the basis of the centered data).
  • These procedures are provided for both the CANDECOMP/PARAFAC model and the Tucker3 model extended with offset terms.
  • The successive and the simultaneous approaches for estimating model and offset parameters have been compared on the basis of simulated data.
  • It was found that both procedures perform well when the fitted model captures at least all offset terms actually underlying the data.
  • The simultaneous procedures performed slightly better than the successive procedures.
  • If fewer offset terms are fitted than there are underlying the model, the results are considerably poorer, but in these cases the successive procedures performed better than the simultaneous ones.
  • All in all, it can be concluded that the traditional approach for estimating model parameters can hardly be improved upon, and that offset terms can sufficiently well be estimated by the proposed successive approach, which is a simple extension of the traditional approach.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28197950.001).
  • [ISSN] 1860-0980
  • [Journal-full-title] Psychometrika
  • [ISO-abbreviation] Psychometrika
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; additive terms / preprocessing / three-way component models
  •  go-up   go-down


92. Lin C, Moore D, DeMichele A, Ollila D, Montgomery L, Liu M, Krontiras H, Gomez R, Esserman L, I-SPY TRIAL Investigators: Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening. J Clin Oncol; 2009 May 20;27(15_suppl):1503
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of locally advanced breast cancer in the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657) in the interval between routine screening.
  • : 1503 Background: It is assumed that most locally advanced breast cancers (LABC) could be detected at an earlier stage with routine screening.
  • However, LABCs may present between screens as interval cancers (IC).
  • ICs present at an earlier age, with higher grade, larger size, and are associated with lower survival, compared to screen-detected cancers (SDC), and comprise 17% of cancers from population-based screening programs.
  • We evaluated the screening history in patients with LABCs from the I SPY TRIAL, to determine the frequency of screening and ICs.
  • METHODS: Of 221 pts enrolled in the I-SPY TRIAL, a multisite neoadjuvant study for women with LABCs > 3cm in size, screening history and presentation were retrospectively collected for 154.
  • Two groups, screened (S), defined as a mammogram within 2 years, or non screened (NS), previous mammogram more than 2 years prior, were evaluated (Table).
  • The frequency of ICs at 1 and 2 years was determined in S pts.
  • Frequency of mammographically occult (MO) tumors was determined for all.
  • RESULTS: Of the total, 99 (64%) and 55 (36%) were NS and S, respectively.
  • Mean tumor size for all pts was 6.7cm.
  • Only 11 (20%) of S pts were SDCs and 44 (80%) were ICs, with 24 (63%) diagnosed within 1 year and 14 (37%) between 1 and 2 yrs of their last normal mammogram.
  • 24 (24%) NS patients were younger than the recommended screening age of 40; in the remaining 75 pts, 9 (12%) were MO.
  • Only 20% of IC tumors were MO.
  • ICs were of higher grade (44% vs 11% grade III), and tumor size (7.0cm vs 4.4cm) than their SDC counterparts.
  • 80% of cancers detected in I SPY were NKI70 gene test poor prognosis.
  • Relationship to breast density and subtype is currently being assessed.
  • CONCLUSIONS: Women presenting with LABCs have a high likelihood (80%) of an IC.
  • This suggests that the growth rate of LABCs precludes early detection by conventional screening.
  • Understanding the biology of ICs will be important to develop better strategies for prevention and early detection.
  • [Table: see text] No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964313.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E, ITMO Study Group: A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial. J Clin Oncol; 2009 May 20;27(15_suppl):5099
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomized, open label, prospective study comparing the association between sorafenib (So) and interleukin-2 (IL-2) versus So alone in advanced untreated renal cell cancer (RCC): Rosorc Trial.
  • Therapy continued until progression of disease or unacceptable toxicity.
  • Eligible pts had histological diagnosis of RCC, ECOG 0-2, no brain metastases, measurable disease and any Motzer's score.
  • Overall disease control rates (PR + stable disease SD) were 81 % versus 74 %.
  • CONCLUSIONS: The safety and efficacy data suggest that the association So + IL-2 is safe and feasible and, compared to So alone, improves tumour shrinkage, disease control rate and PFS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964308.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Goldman S, Coiffier B, Reiter A, Younes A, Cairo MS, International TLS Expert Panel: A medical decision tree for the prophylaxis (P) and treatment (T) of tumor lysis syndrome (TLS): An international TLS consensus panel. J Clin Oncol; 2009 May 20;27(15_suppl):e17575
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 2008) Results: Patients without evidence of LTLS were assigned to either low-risk disease (LRD), medium-risk (MRD), or high-risk (HRD).
  • Risk factors included pathological classification stage, bulk, disease burden (WBC/LDH) and renal impairment/involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963935.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


95. Blay J, Penel N, Italiano A, Duffaud F, Rios M, Collard O, Bertucci F, Isambert N, Chaigneau L, Zintl P: Trabectedin for advanced sarcomas failing doxorubicin: Analysis of 189 unreported patients in a compassionate use program. J Clin Oncol; 2009 May 20;27(15_suppl):10574
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trabectedin for advanced sarcomas failing doxorubicin: Analysis of 189 unreported patients in a compassionate use program.
  • : 10574 Background: Between 2005 and 2008, 387 patients (pts) with advanced sarcoma failing doxorubicin were treated in a compassionate use program (ATU) of trabectedin in France using the standard 1.5mg/m2/CI 24h q21d regimen.
  • The purpose of this study was to assess the outcome of pts treated in this program.
  • METHODS: From 2005 to 2008, 87 centers (ctrs) included at least 1 pt in the ATU program.
  • Inclusion criteria were those of the EORTC trial (J Clin Oncol, 2005;23:5276), with no restriction on the previous number of lines.
  • A simple CRF with 22 items was used to collect pts characteristics and outcome.
  • One hundred eighty-nine pts files were collected as of December 20, 2008.
  • Univariate and multivariate analyses of prognostic factors was performed.
  • RESULTS: Two hundred thirty-five pts were included in the 17 ctrs in which >4 pts were treated.
  • Forty-four ctrs treated only 1 pt.
  • Fifty-two percent were female; major histological subgroups were leiomyosarcoma (29%) and liposarcoma (20%).
  • All pts had been treated with doxorubicin and ifosfamide, 3 (1.5%) in adjuvant setting only.
  • Trabectedin was given in 1st, 2nd, 3rd, or 4th line in metastatic phase in n=8, 69, 66, 42 pts respectively (median: 3rd line).
  • The median number of courses were 3 (range 1-24).
  • Best response reported were PR, n=15 (8%), SD, n=68 (36%) and PD, n=94 (50%), NE, n=11 (6%).
  • With a median follow-up of 805 days (d), median PFS and OS were 91 d and 309 d respectively.
  • 27/127 (20%) evaluable pts had to be hospitalized for treatment related side effects.
  • PFS was superior in myxoid liposarcoma (MyxLPS) (median 192 d vs 69 d, p=0.003), retroperitoneal sarcomas (median 104 d vs 69 d, p=0.006), and grade 1 tumors (median 141 d vs 70 d, p=0.01).
  • In multivariate analysis (Cox model), tumor site, grade 1, histotype were the only independent prognostic factors for PFS.
  • For OS, favorable prognostic factors in univariate analysis were histotypes (MyxLPS, MFH), grade 1 lesions, retroperitoneal site, no hospitalisation for toxicity (p<0.01 all) while Cox model identified female gender, tumor site, histotype as the only independent prognostic factors for OS.
  • CONCLUSIONS: In this compassionate use program for heavily pretreated pts with advanced sarcomas, trabectedin yielded PFS and OS close to those observed in phase II and III trial.
  • PFS and OS are superior in myxLPS, retroperitoneal sarcomas, and grade 1 tumors.
  • [Table: see text].

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963783.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Dookeran KA, Dignam J, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S: p53 as a marker of prognosis in African American (AA) women with breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e22119
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p53 as a marker of prognosis in African American (AA) women with breast cancer.
  • : e22119 Background: Prior reports suggest that p53 may be of prognostic value in AA women with breast cancer.
  • However, it remains to be determined whether p53 status would add prognostic value beyond the commonly used factors of stage and Intrinsic Subtype Classification (subtype).
  • We evaluated p53 status as a prognostic factor among AA women treated at an urban community hospital.
  • METHODS: Cox proportional hazards regression models [results reported as hazard ratios (HR) with 95% confidence intervals (CI)] were used to select and evaluate prognostic factors [including stage, age, tumor grade of differentiation (grade), p53 status, subtype, & ER/PR status] for all-cause mortality in 331 consecutively treated AA women with breast cancer [42 months follow-up] and known subtype [luminal A = ER+, &/or PR+, & HER2-; luminal B = ER+, &/or PR+, & HER2+; HER2+ = ER-, PR-, & HER2+; basal = ER-, PR-, HER2-, cytokeratin (CK) 5/6+ &/or HER1+; & unclassified = negative for all 5 markers] and p53 [Pab1801 antibody] immunohistochemical status.
  • RESULTS: Tumors in 28% of women were p53+ and there were no chemotherapy and radiation treatment differences according to p53 status.
  • However, 59% of p53+ women were ER/PR negative [Odds Ratio (OR), 0.37; 95% CI, 0.22-0.54; p=0.0003] and hence endocrine therapy was significantly less frequent in p53+ women [OR, 0.40; 95% CI, 0.23-0.69; p=0.0008].
  • p53+ tumors were also significantly more likely to be grade 3 [OR, 4.35; CI, 1.33-14.14; p=0.013].
  • Baseline prognostic factors were: stage [(II-IV/I) HR, 2.29; 95% CI, 1.86-2.81; p<0.0001]; age [HR, 1.003 per year; 95% CI, 0.99-1.02; p=0.697]; grade [(high/low) HR, 1.70; 95% CI, 1.22-2.37; p=0.0008]; p53 status [(±) HR, 1.76; 95% CI, 1.15-2.72; p=0.012]; subtype [(all other/luminal A) HR, 1.33; 95% CI, 1.14-1.55; p=0.0004]; ER/PR status [(±) HR, 0.47; 95% CI, 0.32-0.69; p=0.0001].
  • Cox multivariable models indicated that p53 status [HR, 1.59; 95% CI, 1.01-2.51; p=0.044] remained a significant prognostic factor when considered with stage [HR, 2.20; 95% CI, 1.71-2.84; p<0.001] and subtype [HR, 1.24; 95% CI, 1.04-1.49; p=0.016] and the other above-mentioned factors.
  • CONCLUSIONS: Study results indicate that p53 status should be included with stage and subtype as markers to assess prognosis in AA women with breast cancer.
  • No significant financial relationships to disclose.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963516.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Hensel M, Goetzenich A, Hanhoff N, Wolf E, Knechten H, Mosthaf F: Cancer incidence in HIV-positive patients in Germany: A nation-wide survey from 2000 to 2007. J Clin Oncol; 2009 May 20;27(15_suppl):e22115
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The questionnaire requested information on all malignancies in HIV-positive pts, tumor stage, CDC (Center for Disease Control)-stage of the HIV infection, sex, treatment and clinical course.
  • The majority of pts had advanced HIV-disease (CDC stage C3), but the proportion of pts with stage C3 decreased from 58% in 2000 to 36.8% in 2007.
  • 253 (45.8%) were AD as follows: 132 Kaposi Sarcomas, 109 aggressive B-cell lymphomas, 12 invasive cervix carcinomas.
  • The B-cell lymphomas further included 28 Burkitt's lymphomas, 30 DLBCL, 9 Castleman diseases, 8 primary cerebral lymphomas.
  • The number of pts with Hodgkin's lymphoma has increased constantly from 2000 to 2007.
  • The incidence of primary cerebral lymphomas seems to decrease, whereas the incidence of Hodgkin's lymphoma is increasing.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963512.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Godoy J, Cardona AF, Cáceres H, Otero JM, Lujan M, Lopera D, Pacheco JO, Spath A, Gis P: Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study). J Clin Oncol; 2009 May 20;27(15_suppl):e16150
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost-effectiveness analysis of first-line treatment for metastatic renal cell carcinoma (mRCC) in Colombia (ONCOLGroup study).
  • : e16150 Background: Renal cell carcinoma has increased its incidence by 126% since 1950.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963418.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Kolinsky KD, Zhang Y, Packman K, Higgins B: In vivo activity of R1530 (R) alone and in combination with docetaxel (D) and bevacizumab (B) in a prostate carcinoma (PCa) xenograft model. J Clin Oncol; 2009 May 20;27(15_suppl):e16124
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its inhibitory profile includes several kinases that play critical roles in cancer cell growth and division leading to disruption at M-phase and antiangiogenic effects.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963395.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Feldman DR, Sheinfeld J, Bajorin DF, Fischer P, Turkula S, Ishill N, Patil S, Bains M, Bosl GJ, Motzer RJ: Paclitaxel (T) plus ifosfamide (I) followed by high-dose carboplatin (C) and etoposide (E) with autologous stem cell support for patients (pts) with previously treated germ cell tumors (GCT): TI-CE results and prognostic factor analysis in 107 pts. J Clin Oncol; 2009 May 20;27(15_suppl):5027
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel (T) plus ifosfamide (I) followed by high-dose carboplatin (C) and etoposide (E) with autologous stem cell support for patients (pts) with previously treated germ cell tumors (GCT): TI-CE results and prognostic factor analysis in 107 pts.
  • METHODS: Phase I/II trial of TI-CE conducted in GCT pts with progressive disease following chemotherapy and unfavorable prognostic features (extragonadal primary site, IR to first-line therapy, or relapse/IR to ifosfamide/cisplatin-based conventional-dose salvage).
  • 5-yr disease-free survival (DFS) was 47% and overall survival 52% with a median follow-up of 61 months (m).
  • 5/21 (24%) primary mediastinal NSGCT and 2/7 late relapses are continuously disease-free.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962915.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement